Editorial Advisor - James Allan McGregor, MD, CM

OBGYN.net Advertisement

Editorial Advisor - James Allan McGregor, MD, CM - USA

OBGYN.net Editorial Advisor
Obstetrics, Pregnancy & Birth
Correspondent

James Allan McGregor, MD, CM - USA

Archive of Articles and Interviews by Dr. McGregor

Date of Birth: August 2, 1944
Citizenship: United States (Naturalized)

Present Appointments

Senior Technical Physician
Department of Obstetrics and Gynecology
Denver Health Medical Center, Mail Code 0660
777 Bannock Street
Denver, Colorado 80204

Professor, tenured, 1987
Department of Obstetrics and Gynecology, B-198
University of Colorado Health Sciences Center
4200 East 9thAvenue
Denver, Colorado 80262

Adjunct Associate Professor
Department of Food Science and Human Nutrition
Colorado State University
Fort Collins, CO

Graduate Faculty
Department of Preventive Medicine and Biometrics
University of Colorado Health Sciences Center
Denver, CO

Education

Highland Park High School, Highland Park, Illinois
Dartmouth College, 1962-1966 (History Major), B.A.
McGill University, 1966-1970, M.D.C.M.
University of Colorado School of Medicine, Fellow, Maternal-Fetal Medicine 1978-1981

Academics and Professional Appointments

Intern, Rotating/Medicine, Harbor General Hospital, UCLA, Torrance, California, 1970-1971
Resident, Obstetrics and Gynecology, UCLA Medical Center, Los Angeles, California, 1972-73
Chief Resident, Obstetrics and Gynecology, USC Women's Hospital, Los Angeles County, California, 1974-75
Staff Obstetrician-Gynecologist, U.S. Air Force Hospital, Mather Air Force Base, California, 1975-77
Instructor, Family Practice Residency, University of California, Davis, 1975-77
Assistant Professor, Department of Obstetrics and Gynecology, University of Colorado Health Sciences Center, Denver, Colorado, 1977-84
Associate Professor, Department of Obstetrics and Gynecology, University of Colorado Health Sciences Center, Denver, Colorado, 1984-87
Attending Physician, Obstetrics and Gynecology, Denver General Hospital, Denver, Colorado, 1977-78
Fellow, American College of Obstetrics and Gynecology, 1978-Present
Attending Physician, Sexually Transmitted Disease Clinic, University of Colorado Health Sciences Center, Denver, Colorado, 1978-1990
Fellow, Maternal-Fetal Medicine, Department of Obstetrics and Gynecol-ogy, Infectious Disease, University of Colorado Health Sciences Center, Denver, Colorado, 1978-81
Attending Physician, Pediatric Infectious Disease, University of Colorado Health Sciences Center, Denver, Colorado, 1984-85
Attending Physician, Sexually Transmitted Diseases, Denver Metropolitan Clinic, Denver General Hospital, Denver, Colorado, 1980
Instructor, Center for Disease Control, Region VIII, Sexually Trans-mitted Disease Program,
Denver, Colorado, 1980-1995

Administrative Experience
Departmental:

Interim Chairman, Department Obstetrics and Gynecology
University of Colorado Health Sciences Center, April 1988 - March 1989
Interim Chief, Division of Obstetrics University Hospital, 1988-1989
Executive Committee, University Hospital, 1988-1990
Vice Chairman of Academic Affairs, Department Obstetrics and Gynecology
University of Colorado Health Sciences Center, 1989-Present
Chair, Department of Obstetrics and Gynecology Committee for Promotion and Tenure
University of Colorado Health Sciences Center, 1989-Present
Member, Department of Obstetrics and Gynecology Department Academic Enrichment
Fund Committee, University of Colorado Health Sciences Center, 1990-1993
Resident Education Committee, 1992-Present
Chair, Ad Hoc Resident Research Committee, 1993-Present

University of Colorado Health Sciences Center and University Hospital:

Chair, Nominating Committee Medical Board, 1991
Member, Nominating Committee Medical Board, 1989-1990
Member, Medical Board, 1988-1989
Member, Continuing Medical Education Committee, 1990-Present
Member, Pharmacy and Therapeutics Committee, 1981-Present
Vice-Chair, Pharmacy and Therapeutics Committee, 1986-1988
Member, Infection Control Committee, 1981-1990
Member, Committee on AIDS, 1986-1988
Member, Medical Records Committee, 1986-1988
Member, Working Group Health Care Policy Center Institution, 1992-1994
Member, Faculty Promotions and Tenure Committee, 1995-present
Member, Faculty Finance and Incentive Plan Committee, 1995-present

Local and National:

Member, Planned Parenthood Federation of America, 1983-Present
Chair, Planned Parenthood, National Medical Standards Committee, 1990-1992
Member, PPFA, National Medical Board 1989-1992
Member, Standards Committee, National Medical Board, 1989-1990
Chair, Rocky Mountain Planned Parenthood Medical Board, 1984-1986
Member, Rocky Mountain Planned Parenthood Medical Board, 1983-Present

Medical Societies:

Program Chair, Colorado OB/GYN Society, 1986-1992
Executive Board, Colorado OB/GYN Society, 1986-Present
President-Elect, Colorado OB/GYN Society, 1990-1991
President, Colorado OB/GYN Society, 1991-1992
Past President, Colorado OB/GYN Society, 1992-93
Secretary, Infectious Disease Society for Obstetrics and Gynecology, 1998-1999

State Licensure

L.M.C.C. in Canada, 1971
State of California, 1971-Present
State of Colorado, 1977-Present

Certification

Board Eligible, Maternal-Fetal Medicine 1980
American Board of Obstetrics and Gynecology, 1977

Academic Honors

Lange Medical Publication Award for Academic Excellence, 1969
Wood Memorial Gold Medal - Highest Standing Senior in Medical School Class
Gold Medal - Medical School Class Highest Standing
Frederick Smith Memorial Scholar, 1969-1970
McGill University Scholarship, 1969-1970
Gold Medal Award in Obstetrics and Gynecology
Mr. and Mrs. J.A. Besner Prize, McGill University Faculty of Medicine
Highest Standing Award - Obstetrics and Gynecology, McGill University Faculty of Medicine
Highest Standing Award - Surgery, McGill University Faculty of Medicine
Highest Standing Award - Medicine, McGill University Faculty of Medicine
Highest Standing Award - Psychiatry, McGill University Faculty of Medicine
Highest Standing Award - Ophthalmology, McGill University Faculty of Medicine
Chancellor's Faculty Research Award, University of Colorado Health Sciences Center, Denver, Colorado, 1984
First Prize Paper: District VIII ACOG Meeting: "Intrauterine and Postpartum Prevention of Rh-Isosensitization in the Neonate," October, 1976
Second Prize Paper: 34th Annual Clinical ACOG meeting: A "Bacterial Protease-induced Reduction of Chorioamniotic Membrane Strength and Elasticity." May, 1986
First Prize Paper: District VIII ACOG Annual Meeting, Palm Desert, CA, October 1-4, 1988: "Cervico-vaginal microbial-host interaction and maternal and perinatal outcome: Refining the hypothesis."
Resident's Recognition Award, 1989, Department Ob/Gyn, University of Colorado
Citation - American Board of Medical Specialties, 1992-Present
Best Doctors in America - 1992-1993 Edition, 1994-1995 Edition, 1997 Edition
Who's Who in American Medicine, 1993, 1994, 1995, 1996
Most Outstanding Faculty Member Teaching Award, 1994
Who's Who in the West, 25th Edition, 1994
Who's Who in Science and Engineering, 3rd Edition, 1995- Present
International Who's Who in Medicine, 2nd Edition, 1995
Sterling Who's Who, Executive Edition, 1995-96
Marquis Who's Who, Official ABMS Directory of Board Certified Medical Specialists, 30th edition, 1997
The Best Doctors in America: Central Region, 1996-97
The Best Doctors for Women, Good Houskeeping magazine, August, 1997

Other Activities

Lecturer, University of Colorado School of Medical Technology, 1978-Present
Director, Young Mother's Service, University of Colorado Health Sciences Center, 1980-1983
Lecturer, Core Curriculum, Department of Pediatrics, University of Colorado Health Sciences Center, 1980-1988
Lecturer, Medical Student Course in Research (Chair, Dr. Michael Glode, 1989-1994)
Lecturer, Child Health Associate Program, University of Colorado Health Sciences Center, 1979-1988, 1994, 1995
Director, Therapeutic Abortion Service, University of Colorado Health Sciences Center, 1978-1985
Member, Planned Parenthood of the Rocky Mountain Physicians' Education Com-mittee, 1980-1982
Consultant, The American College of Obstetrics and Gynecology Task Force on Native American Health, 1980-1986
Originator and Faculty, Twice-Yearly Continuing Programs on Reproductive Health for the School Boards and Districts of Colorado Springs, Pueblo, LaJunta, Lamar, and Boy's Ranch, Colorado, 1978-1982
Member, Partners, Inc. (Denver, Colorado Court Agency), 1979-1980
Member, Development Associates, Family Planning Education and Technol-ogy in Federal District VIII, Denver, Colorado, 1979
Adjunct Member, Colorado Association of Sex Therapists, 1980-1985
Participant, Perinatal Outreach Program, Denver Children's Hospital, 1981-1985
Consultant and Instructor, Department of Obstetrics and Gynecology, Pediatrics and Nursing: Denver General Hospital, Rose Medical Center, St. Joseph's Hospital, Swedish Hospital, Denver, Colorado
Instructor, Course in Human Lactation, School of Medicine, 1980-1983
Board Member, SHARE Inc. (for Lay and Medical Education), 1982-1983
Faculty, Medical Liaison Section, Merck Sharp and Dohme, 1981-Present
Course Director: "Sexually Transmitted Diseases - Issues and Answers for the 80s." London, England, July 17-25, 1981
Course Co-Director: "Sexually Transmitted Diseases - Issues and Answers for the 80s." Keystone, Colorado, January 25 - February 2, 1982
Reproductive Medicine Consultant, Colorado State Board of Health, 1982-Present
Lecturer, The American College of Obstetrics and Gynecology Task Force on Native American Health
Co-Chairman, Society for Adolescent Medicine, Rocky Mountain Chapter, 1982 Conference. "Issues in Adolescent Reproductive Care," Denver, Colorado, April 12, 1982
Program Chairman, Annual Physicians Meeting, Department of Obstetrics and Gynecology and Share Center, Denver, Colorado, March 3-6, 1983
Program Chairman, Fertility Awareness: Natural Family Planning, Depart-ment of Obstetrics and Gynecology, Archdiocese of Denver, Depart-ment of Health, October, 1982
Program Co-Chairman, Adolescent Reproductive Struggles, Department of Obstetrics and Gynecology, University of Colorado Health Sciences Center, Society for Adolescent Medicine, Denver, Colorado, April 16-18, 1982
Member, Strategic Planning Committee, Rocky Mountain Planned Parenthood, 1983
Vice-Chairperson, Western Region Medical Committee, Planned Parenthood Federation of America, 1984
Medical Staff, Children's Hospital, Denver, Colorado, 1986-Present
Program Chairperson, Association of Planned Parenthood Professionals (APPP), Postgraduate Course "Treatment and Diagnosis of Sexually Transmitted Diseases in Family Planning Clinics", National Meeting of the Planned Parenthood Federation of America. October 16-20, 1986, New Orleans, LA
Planning Committee Member, John Snow Inc. (JSI) Research and Training, 1986-1988 Institute, Regional District 8, Denver, CO, 1986-Present
Medical Staff, Department of Surgical Specialties/Gynecology, Children's Hospital, Denver, CO, 1986-Present
Consultant, John Snow Inc. (JSI) International Program, 1986-1994
Medical Staff, St. Anthony's Hospital Central, 1993-Present
Member, University of Colorado Health Sciences Center Committee for AIDS, 1987-1989
Participant, Symposium on Beta-Lactamase Inhibition: Therapeutic Implications in Obstetrics and Gynecology, November 12-15, 1987, Phoenix, Arizona
Member, Dartmouth Class of '66 Executive Committee, 1991-1993
Nominated, Central Travel Club, 1988, 1990
Residency Selection Committee, Department Obstetrics and Gynecology, 1988.
Executive Committee, University of Colorado Center for Health Science, 1988-1989.
Governor's Task Force for Care of Pregnant Women and Infertility, State of Colorado, 1988
Instructor, Epidemiology of Communicable Disease (PRM 6635), 1989
Member, Scientific Advisory Board, II nd World Congress for Infectious Disease in Obstetrics and Gynecology, September 7-14, Bangkok, Thailand
Member, Scientific Advisory Board, World Congress for Infectious Diseases in OB/GYN 1990, 1991
Committee Member, Promotions and Tenure Committee, University Hospital, 1990-1992
Member, Tutorial Systems International (TSI) Ashford, Kent, UK, 1987-Present
Member, Thesis Committee, Laura Wood, Master of Science, 1988, Department of Nutrition Science, Colorado State University, 1989
Consultant, National Institutes of Health, 1990-1994, 1995
Consultant, National Science Foundation, 1985-1993
Committee Member, American Foundation for AIDS Research, 1993-1995
Instructor, Colorado AIDS Education and Training Center: Mini-Sabbatical Program, 1993-Present
Member, Expert Reviewer, Panel for HIV Infected HealthCare Providers, Colorado Department of Public Health and Environment, 1993-Present
Committee Member, Maternal Mortality Review Committee, State of Colorado, Department of Public Health and Environment, 1993-Present
Lecturer, University of Colorado Neonatology Services, 1993
Chair, Associate of Reproductive Health Professions, "Update in STDs", 1993
Nominated, President of American Venereal Disease Association, 1994
Scientific Exhibit, American Society of Hospital Pharmacists, Miami, FL, December 6, 1994
Member, Ph.D. Committee, Melanie Reece. Colorado State University Department of Food Service and Nutrition, 1995
Member, Ph.D. Thesis Committee, Dr. Helen MacDonald, 1995
Lecturer, "Perinatal Infection Workshop," hosted by National Center for Infectious Diseases. Centers for Disease Control, Atlanta, GA, October 27-28, 1994
Special Consultant to the National Center for Infectious Diseases. Centers for Disease Control, Group B Streptococcal Management in Pregnancy Guidelines, 1996
Reviewer, Student Research Forum, University of Colorado Health Sciences Center, 1997
Member, Planned Parenthood of the Rocky Mountains Medical Advisory Panel, 1997

Academic and Professional Societies

Board Member, Associates of Reproductive Health Professionals (ARHP), 1992-95
Faculty, European Institute for Advanced Medical Teaching, 1994
Member, Scientific Advisory Board for the Third International Conference of Vaginitis/Vaginosis, 1994
Chair, STD Expert Panel Committee, Association for Reproductive Health Professionals, 1994
Society for Gynecologic Investigation (SGI), 1987-Present
Society for Perinatal Obstetricians (SPO), 1988-Present
Former Residents Obstetrical and Gynecologic Society of LAC-USC Medical Center (FROGS)
Denver Medical Society 1978-1979
Colorado Medical Society 1978-1979
Dartmouth College Alumni Association
McGill University Alumni Association
American Society for Microbiology, 1981-Present
Association of Reproductive Health Professionals, 1985-Present
Association of Planned Parenthood Professionals, 1978-1985
Society for Adolescent Medicine, Rocky Mountain Chapter 1980-1982
American Venereal Disease Association (AVDA), 114982-Present
American Public Health Association 1982-Present
Population and Family Planning Section, American Public Health Associa-tion, 1982-Present
American Society for Rickettsiology and Rickettsial Diseases 1983-1985
Infectious Disease Society for Obstetrics-Gynecology 1986-Present
Central Association of Obstetricians and Gynecologists 1986-Present
The Southwest Obstetrical and Gynecological Society, Honorary Member, 1987-Present
Colorado Ob/Gyn Society, 1990-Present
American College of Obstetricians and Gynecologists, 1977-Present
Rocky Mountain Branch, American Society for Microbiologists, 1981-Present
Member, The Lula O. Lubchenco Center for Perinatal Research, Education, Follow-up and Epidemiology, 1988-Present
Overseas Fellow, Royal Society of Medicine, London, 1989-Present
American Association for the Advancement of Science, 1992-Present
International Immunocompromised Host Society, 1990-Present
Society of Physicians for Reproductive Choice and Health, 1995-Present
National Women's Health Network, 1994-Present
Association of Reproductive Health Professionals, 1996-Present
Chancellor's Society at the University of Colorado Health Sciences Center, 1996-Present

Reviewer

American Journal of Obstetrics and Gynecology
Obstetrics and Gynecology
American Society of Microbiology, Newsletter
Infectious Diseases
Birth
International Journal of Feto-Maternal Medicine - Basic and Clinical Research, Clinical Experience (Munich, Germany)
National Science Foundation, 1982-Present
Journal of Infectious Disease in Obstetrics and Gynecology, Editorial Board, 1993-present
34th Annual Clinical Meeting, American College of Obstetrics and Gynecology, May 3, l986
Fertility and Sterility, 1988-Present
March of Dimes, 1988-Present
American Foundation for AIDS Research, 1992-Present
Journal of Infectious Disease for Obstetrics and Gynecology, 1992-Present
Infection Control and Hospital Epidemiology, 1992-Present
American Social Health Association Research Fund (ARF), 1995
Abstract Reviewer, Society for Gynecologic Investigation, 1995
American Journal of Public Health, 1995
New England Journal of Medicine 1996, Placenta 1998.
New England Journal of Medicine, 1999
International Journal of Laboratory Medicine and Molecular Diagnostics
Reviewer Board of Regents State of Louisiana

Editorial Experience

Editorial Board Member, Journal of Infectious Diseases in Obstetrics and Gynecology, 1992 - present
Co-Editor, Textbook of Gynecology, WB Saunders, Philadelphia, 1991-1993
Editorial Board, International Journal of Feto-Maternal Medicine-Basic and Clinical Research, Clinical Experience (Munich, Germany)
Regional Editor, The Infectious and Medical Disease Letters for Obstetrics and Gynecology
Guest Editor, Festschrift for Dr. Tommy Evans, Journal of Reproductive Medicine, 1990
Editorial, Acute Communicable Disease Control, County of Los Angeles Department of Health Services, Los Angeles, California, 1993
Editorial Board, Tutorial Systems International, Continuing Education in Obstetrics and Gynecology, 1993 - present
Editorial, Infection Control and Hospital Epidemiology, September, 1993, Prevention of Rubella: Missed Opportunities
Doody's Rating Service: A Buyer's Guide to the 250 Best Health Sciences Books, 1993
Co-Editor, Textbook Gynecology, WB Saunders, 1996 publication
Editorial Board, International Journal Fetal-Maternal Medicine, 1990-present
Editorial Board, Journal of the Society for Gynecologic Investigation, 1993
Associate Editor, Tutorial Systems International, International Tutorials, 1996
Editorial Advisory Board, Journal of Reproductive Medicine, 1996

Journal Publications (Peer Reviewed)

1. Hoffman AA, Hayward AR, Kurnick JT, Defreitas EC, McGregor JA, Har-beck RJ. Presentation of antigen by human newborn monocytes to maternal tetanus toxoid-specific t-cell blasts. J Clin Immunol 1(4):217-221, 1981.

2. McGregor JA, Burns JC, Levin MJ, Meiklejohn G. Transplacental pas-sage of influenza A/Bangkok (H3N2) mimicking amniotic fluid infection syndrome. Am J Obstet Gynecol 149(8):856-859, 1984.

3. McGregor JA, Ott A, Villard M. An epidemic of childbed fever. Am J Obstet Gynecol 150:385-388, 1984.

4. McGregor JA, Meeuwsen J. Autonomic hyperreflexia: A mortal danger to spinal cord-damaged women in labor. Am J Obstet Gynecol 151(3):330-333, 1985.

5. McGregor JA. Adolescent misadventures with urethritis and cer-vicitis. Adolescent Health Care 6(4):286-297, 1985.

6. McGregor JA, Lawellin D, Franco-Buff A, Todd JK, Makowski EL. Protease production by microorganisms associated with reproductive tract infection. Am J Obstet Gynecol 154(1):109-114, 1986.

7. McGregor JA, French JI, Reller LB, Todd JK, Makowski EL. Ad-junctive erythromycin treatment for idiopathic preterm labor: Results of a randomized, double-blinded, placebo-con-trolled trial. Am J Obstet Gynecol 154(1):98-103, 1986.

8. McGregor JA, Ogle JW, Curry-Kane G. Perinatal pertussis. Obstet Gynecol 68(4):582, 1986.

9. McGregor JA, Kleinschmidt-DeMasters BK, Ogle J. Meningoen-cephalitis caused by Histoplasma capsulatum complicating preg-nancy. Am J Obstet Gynecol 154(4):925-931, 1986.

10. McGregor JA, French JI, Makowski EL. Single-dose cefotetan versus multi-dose cefoxitin for prophylaxis in cesarean sec-tion in high-risk patients. Am J Obstet Gynecol 154(4):955-960, 1986.

11. McGregor JA. Toxic shock syndrome: six years later. A review. J Obstet Gynaecol 6 (Suppl 1):S52-S57, 1986.

12. McGregor JA, Guberman A, Amer J, Goodlin R. Idiopathic facial nerve paralysis (Bell's palsy) in late pregnancy and the early puer-perium. Obstet Gynecol 69(2):435-8, 1986.

13. McGregor JA, Mark S, Crawford GP, Levin MJ. Varicella Zoster antibody testing in the care of pregnant women exposed to varicella. Am J Obstet Gynecol 157(2):281-284, 1987.

14. McGregor JA, French JI, Lawellin D, Franco-Buff A, Smith C, Todd JK. In vitro study of bacterial protease-induced reduc-tion of chorioamniotic membrane strength and elasticity. Obstet Gynecol 69(2):167-174, 1987.

15. McGregor JA, Duncan LS. Suing as somatization. Am J Obstet Gynecol 158:616-7, 1988.

16. Ellison RT, McGregor JA. Recurrent postcoital lower-extremity strep-tococcal erythroderma in women. Streptococcal Sex Syndrome. JAMA 257(23):3260-2, 1987.

17. McGregor JA, Mark S, Crawford GP, Levin MJ. Varicella zoster antibody testing in the care of pregnant women exposed to varicella. Am J Obstet Gynecol 157(2):281-4, 1987.

18. Hershey DW, McGregor JA. Low prevalence of Toxoplasma gondii infection in a Rocky Mountain prenatal population. Obstet Gynecol 70(6):900-902, 1987.

19. McGregor JA, French JI, Spencer NE. Prevention of Sexually Transmitted Diseases in Women. J Reprod Med 33(1):109-118, 1988.

20. McGregor JA, French JI, Lawellen D, Todd JK. Preterm birth and infection: Pathogenic possibilities. Amer J Reprod Immunology and Microbiology 16(3):123-32,1988.

21. McGregor JA, Christensen F, Reller L. Treatment of obstetric and gynecologic infections, with an emphasis on beta-lactamase producing organisms. Reprod Med 33(6):591-4, 1988.

22. McGregor JA, French JI, Richter R, Hillier S, Christensen F, Lawellin D, Franco-Buff A, Todd JK. Microbial & Clinical Correlations in Evaluation of Preterm Birth. Annals New York Academy of Science, Impact on the Fetus and Parental Sexually Transmitted Disease, New York, pages 234-236, 1988.

23. McGregor JA, French JI, Richter R, Hillier S, Christensen F, Lawellin D, Franco-Buff A, Todd JK. Preterm Birth and Cervicovaginal Microbiologic-Host Interactions. Annals New York Academy of Science, Impact on the Fetus of Parental Sexually Transmitted Disease, New York, pages 236-238, 1988.

24. McGregor JA, French JI, Lawellin D, Franco-Buff A, Richter R, Christensen F, Todd JK. Aspects of Cervico/Vaginal Microorganisms and Maternal-Host Defense in the Pathogenesis of Premature Labor and Birth. Annals New York Academy of Science, Impact on the Fetus and Parental Sexually Transmitted Disease, New York, pages 238-241, 1988.

25. McGregor JA, Gordon SF, Krotec J, Poindexter AN. Results of randomized, multi-center, comparative trial of single dose of cefotetan versus multiple doses of cefoxitin as prophylaxis in cesarean section. Am J Obstet Gynecol 158:701-6, 1988.

26. McGregor JA. Are neonatal scalp abscesses another complication of bacterial vaginosis? Ped Infect Dis J 7(6):437-438, 1988.

27. Galask RP, Benigno BB, Cunningham FG, Elliott JP, Makowski E, McGregor JA, Poindexter A. Results of a multi-center comparative study of single-dose cefotetan and multiple-dose cefoxitin as prophylaxis in patients undergoing cesarean section. Am J Surg 155(5A):86-90, 1988.

28. Berkeley AS, Freedman KS, Ledger WJ, Orr JW, Benigno BB, Gordon SF, McGregor JA, Galask RP, Sevin BU. Comparison of cefotetan and cefoxitin prophylaxis for abdominal and vaginal hysterectomy. Am J Obstet Gynecol 153:3(2):706-9, 1988.

29. McGregor JA, McFarren T. Neonatal cranial osteomyelitis: a complication of fetal monitoring. Obstet Gynecol 73(2):490-2, 1989.

30. McGregor JA, Soper De, Lovell G, Todd JK. Maternal deaths associated with Clostridium sordelli infection. Am J Obstet Gynecol 161:987-95, 1989.

31. Schoonmaker JN, Lawellin DW, Lunt B, McGregor JA. Bacteria and inflammatory cells reduce chorioamniotic membrane integrity and tensile strength. Obstet Gynecol 74:590-6, 1989.
32. McGregor JA, Christensen FB. A comparison of ampicillin plus sulbactam versus clindamycin and gentamicin for treatment of postpartum infection. Intl J Obstet Gynecol 2:35-39, 1989.

33. McGregor JA, Rubright G, Ogle J. Congenital cytomegalovirus infection as a preventable complication of maternal transfusion. J Reprod Med 35(1):61-64, 1990.

34. McGregor JA, French JI, Richter R, et al. Antenatal microbiologic and maternal risk factors associated with prematurity. Am J Obstet Gynecol 163;1465-73, 1990.

35. McGregor JA, Schoonmaker JN, Lunt BD, Lawellin DW. Antibiotic inhibition of bacterially-induced fetal membrane weakening. Obstet Gynecol 76(1):124-8, 1990.

36. McGregor JA, French JI, McKinney PJ, Milligan K. Comparison of single-dose ceftizoxime with multi-dose cefoxitin chemoprophylaxis for patients undergoing hysterectomy. Clin Therapeutics 12 (Suppl C):45-52, 1990.
37. Seo K, McGregor JA, French JI. Infection and premature rupture of the membranes. Fetal Medicine Rev 2:1-19, 1990.

38. McGregor JA, French JI, Richter R, et al. Cervicovaginal microflora and pregnancy outcome: Results of a double-blind, placebo-controlled trial of erythromycin treatment. Am J Obstet Gynecol 163:1580-91, 1990.

39. Wada SJ, McGregor JA. Management of Bartholin's Abscesses: Three Years Experience. Infect and Med Dis Ltrs for Ob Gyn XII(3):59-64, 1990.

40. Schoonmaker JN, Lunt BD, Lawellin DW, French JI, Hillier SL, McGregor JA. A new proline aminopeptidase assay for diagnosis of bacterial vaginosis. Am J Obstet Gynecol 165:737-742, 1991.

41. McGregor JA, French JI. Chlamydia trachomatis infection during pregnancy. Am J Obstet Gynecol 164:1782-1789, 1991.

42. McGregor JA, French JI, Seo K. Adjunctive clindamycin therapy for preterm labor: Results of a double-blind, placebo-controlled trial. Am J Obstet Gynecol 165:867-75, 1991.

43. McGregor J, French JI, Seo K. Antimicrobial therapy in preterm premature rupture of membranes: Results of a prospective, double-blind, placebo-controlled trial of erythromycin. Am J Obstet Gynecol 165:632-40, 1991.

44. McGregor JW, Lawellin DW, Franco-Buff A, Todd JK. Phospholipase C activity in microorganisms associated with reproductive tract infections. Am J Obstet Gynecol 164:682-6, 1991.

45. McGregor JA, Christensen FB, French JI. Intramuscular Imipenem/Cilastatin treatment of upper reproductive tract infection in women: Efficacy and use characteristics. Chemother 37(suppl 2):31-36, 1991.

46. Stamm E, Waldstein G, Thickman D, McGregor J. Amniotic sheets: Natural history and histology. J Clin Ultrasound 10(9):501-4, September 1991.

47. Silver B, Heddleston L, McGregor J, Gibbs R. Life-threatening puerperal infection due to group A streptococci. Obstet Gynecol 79(5(pt.2)):894-6, May 1992.

48. Seo K, McGregor J, French J. Preterm birth is associated with increased risks of maternal and neonatal infections. Obstet Gynecol 79:75-80, 1992.

49. Day D, Ugol JH, French JI, Havercamp A, Wall RE, McGregor JA. Fetal monitoring in perinatal sepsis. Amer J Perin 9:28-33, 1992.

50. McGregor JA, Leff CM, Orleans M, Baron A. Fetal gender differences in preterm birth: findings in a North American cohort. Amer J Perinat 9:43-48, 1992.

51. Heyborne KD, Witkin SS, McGregor JA. Tumor necrosis factor-a in mid-trimester amniotic fluid is associated with impaired intrauterine fetal growth. Am J Obstet Gynecol 167(4):920-925, 1992.

52. McGregor JA, French JI, Jones W, Parker R, Patterson E, Draper D. Association of cervicovaginal infections with increased vaginal fluid phospholipase A2 activity. Am J Obstet Gynecol 167(6):1588-94, 1992.

53. Lavin JA, McGregor JA. Native American childbirth on the western plains. Intl J Feto Mat Med, 5(3):125-132, 1993.

54. Draper D, Parker R, Patterson E, Jones W, Beutz M, French J, Borchardt K, McGregor JA. Detection of Trichomonas vaginalis in pregnant women with the InPouch TV culture system. J Clin Micro 31(4):1016-18, 1993.

55. McGregor JA, French JI, Seo K. Premature rupture of membranes and bacterial vaginosis. Am J Obstet Gynecol 169(2):463-466, 1993.

56. McGregor JA, Hammill HA. Contraception and sexually transmitted diseases: Interactions and Opportunities. Am J Obstet Gynecol 168(6 Pt. 2):2033-41,1993.

57. McDuffie RS, McGregor JA, Gibbs RS. Adverse perinatal outcome and resistant enterobacteriaceae after antibiotic usage for premature rupture of the membranes and group B streptococcus carriage. Obstet Gynecol 82(1):487-489, 1993.

58. Silver RM, Schwinzer B, McGregor JA. Interleukin-6 levels in amniotic fluid in normal and abnormal pregnancies: Preeclampsia, small-for -gestational-age fetus, and premature labor. Am J Obstet Gynecol 169: 1101-5, 1993.

59. Livengood CH, McGregor JA, Soper DE, Newton E, Thomason JL. Bacterial vaginosis: efficacy and safety of intravaginal metronidazole treatment. Am J Obstet Gynecol 170:759-64, 1994.

60. Sweet RL, Roy S, Faro S, O'Brien WF, Sanfilippo JS, Seidlin M, McGregor J. Piperacillin and Tazobactam Versus Clindamycin and Gentamicin in the Treatment of Hospitalized Women With Pelvic Infection. Obstet Gynecol 83(2):280-285, 1994.

61. McFarren T, Koch S, McGregor JA. Cervical ripening and labor induction with an intravaginal prostaglandin E2 suppository: experience in a community hospital. International Journal of Feto-Maternal Medicine 6(1):5-10, 1994.

62. Gibbs RS, McGregor JA, Mead PB, Eschenbach DA, Hager WD, Sweet RL. A Survey of Practices in Infectious Diseases By Obstetrician-Gynecologists. Obstet Gynecol 83(4):631-636 1994.

63. McGregor JA, French JI, Jones W, Milligan K, McKinney P, Patterson E, Parker R. Bacterial Vaginosis Is Associated With Prematurity and Vaginal Fluid Mucinase and Sialidase: Results of a Controlled Trial of Topical Clindamycin Cream. Am J Obstet Gynecol 170:1048-60, 1994.

64. Gonik B, McGregor JA. A Comparison of Short Versus Long Half-life Single-dose Prophylactic Antibiotics for Cesarean Section. Infectious Diseases in Obstetrics and Gynecology. (In press, 1994).

65. Heine RP, McGregor JA, Patterson E, Parker R, Draper D, French J, Jones W. Trichomonas vaginalis: Diagnosis and Clinical Characteristics in Pregnancy. Infectious Diseases in Obstetrics and Gynecology 1:228-234, 1994.

66. Stevens-Simon C, Jamison J, McGregor J, Douglas J. Racial Variation in Vaginal pH Among Healthy Sexually Active Adolescents. Sexually Transmitted Diseases 21(3):168-172, May-June 1994.

67. McGregor JA, Phillips LE, Roy S, Dunne JT, Warwaruk AS, Johnston DW, Yuzpe AA, Hemsel DL. Results of a Double-Blind, Placebo-Controlled Clinical Trial Program of Single-Dose Ceftizoxime versus Multiple-Dose Cefoxitin as Prophylaxis for Patients Undergoing Vaginal and Abdominal Hysterectomy. J Am Coll Surg 178:123-131, 1994.

68. McGregor JA, Crombleholme WR, Newton E, Sweet T, Tuomala R, Gibbs RS. Randomized Comparison of Ampicillin-Sulbactam to Cefoxitin and Doxycycline or Clindamycin and Gentamicin in the Treatment of Pelvic Inflammatory Disease or Endometritis. Obstet Gynecol 83:998-1004, 1994.

69. Jeremias J, Draper D, Ziegert M, Jones M, Inglis S, McGregor JA, Witkin S. Detection of Trichomonas vaginalis Using the Polymerase Chain Reaction in Pregnant and Non-Pregnant Women. Infectious Diseases in Obstetrics and Gynecology 2:16-19, 1994.

70. Heyborne KD, McGregor JA, Henry G, Witkin SS, Abrams JS. Interleukin-10 in amniotic fluid at mid-trimester: Immune activation and suppression in relation to fetal growth. Am J Obstet Gynecol 171:55-9, 1994.

71. Draper D, Jones W, Heine RP, Beutz M, French JI, McGregor JA. Trichomonas vaginalis Weakens human amniochorion in an in-vitro model of premature membrane rupture. Inf Dis Obstet Gynecol 2:267-74, 1995.

72. McGregor JA, French JI, Parker R, Draper D, Patterson E, Jones W, Thorsgard K, McFee J. Prevention of premature birth by screening and treatment for common genital tract infections: Results of a prospective controlled evaluation. Am J Obstet Gynecol 173:157-67, 1995.

73. McGregor JA, Jackson MG, Lachelin GL, Goodwin TM, Artal R, Hastings C, Dullien V. Salivary Estriol as Risk Assessment for Preterm Labor: A Prospective Trial. Am J Obstet Gynecol 173(4):1337-42, 1995.

74. Draper D, Hall J, Jones W, Beutz M, Heine RP, Porecco R, McGregor JA. Elevated protease activities in human amnion and chorion correlate with preterm premature rupture of membranes. Am J Obstet Gynecol 173: 1506-12, 1995.

75. Binkley S, McGregor JA. The New Paradigm for the Prevention and Management of Pelvic Inflammatory Disease and Common Bacterial STDs in Women and Their Partners: Using Nucleic Acid Amplification and Single-Dose Regimens. The J Clinical Practice in Sexuality 10(5/6):5-11, May, June 1995.

76. Devoe LD, Artal R, Goodwin TM, Weiner C, Witter F, McGregor JA, et al. A multi-center randomized controlled trial of home uterine monitoring: Active versus sham device. Am J Obstet Gynecol 173(4):1120-27, 1995.

77. Iams JD, Casal D, McGregor JA, Goodwin TM, Kreaden US, Lowensohn R, Lockitch G. Fetal fibronectin improves the accuracy of diagnosis of preterm labor. Am J Obstet Gynecol 173(1): 141-5, 1995.

78. DeMeo LP, Draper DL, McGregor JA, Moore DF, Peter CR, Kapernick PS, McCormack WM. Evaluation of a deoxyribonucleic acid probe for the detection of Trichomonas vaginalis in vaginal secretions. Am J Obstet Gynecol 174(4):1339-42, 1996.

79. Reece MS, McGregor JA, Allen KGD, Mathias MM, Harris MA. Prostaglandins in selected reproductive tissues in preterm and full term gestations. Prostaglandins 55(5):303-307, 1996.

80. McGregor JA, Roberts AM. First antenatal visits and metronidazole. Am J Obstet Gynecol 176(4):887-888, 1997.

81. Reece MS, McGregor JA, Allen KG, Harris MA. Maternal and perinatal long chain fatty acids: possible roles in preterm birth. Am J Obstet Gynecol 176(4):907-914, 1997.

82. McGregor JA, French JI. Evidence-based prevention of preterm birth and rupture of membranes: infection and inflammation. J Soc Obstet Gynaecol Can 1997;19:835-852, 1997.

83. Gall S, Hemsell DL, McGregor JA, Martens MG, Pitkin D, Allen S. Tissue penetration of meropenem in gynecologic surgery patients. Clin Infect Dis, (In press, 1997)

84. McGregor, JA, French, JI. Disease Management Strategies for Preventing Preterm Birth Reproductive Tract Infections. Drug Benefit Trends, November 1997.

85. Shroyer KR, Thompson C, Enomoto T, Eskens JL, Shroyer, AL, McGregor JA. Telomerase Expression in Normal Epithelium, Reactive Atypia, Squamous Dysplasia, and Squamous Cell Carcinoma of the Uterine Cervix. Am J Clin Path 109:2, 1998.

86. duBouchet L, Pa-C, McGregor JA, Ismail M, McCormack, WM. A Pilot Study of Metronidazole Vaginal Gel Versus Oral Metronidazole for the Treatment of Trichomonas vaginalis. STD, 25(3): 176-9, 1998.

87. McGregor JA, Prevention of preterm birth published in New England Journal of Medicine
339/25 (1998), p 1858-1859

88. Janice IF, McGregor JA, Deborah Draper, Ruth Parker, John McFee. Gestational Bleeding, Bacterial Vaginosis, and Common Reproductive Tract Infections: Risk for Preterm Birth and Benefit of Treatment

89. JA McGregor, W.D.Hager, R.S. Gibbs, L. Schmidt, and J. Schulkin.. Assessment of Office-Based Care of Sexually Transmitted Diseases and Vaginitis and Antibiotic Decision-Making by Obstetrician-Gynecologists. Infectious Dis. In Obstetrics and Gynecology 6:247-251(1998)

Submitted for Publication
Draper D, Jones W, French JI, McGregor JA. Trichonomas vaginalis makes phospholipase A2 and C. (Submitted 1995)

French JI, McGregor JA, Draper D, Parker R, McFee J. Early gestational bleeding and bacterial vaginosis increase risks of preterm birth. (Submitted July, 1997)

Draper D, Jones W, Heine R, McGregor JA. Protease activity of Trichomonas vaginalis cleaves fetal fibronectin and limits the ability to detect the molecule. (In preparation 1996)

McGregor JA, Kelley PJ, Brosky CR, Moran KA, Reznikov LL. Comparison of a two minute water-insoluble Iodophorin alcohol (DuraprepTM) and a five minute aqueous iodophor presurgical scrub skin preparation among women undergoing cesarean section: Results of a controlled trial. (In preparation 1996)

Heine RP, Draper D, Jones W, French JI, McGregor JA. Vaginal fluid enzymes correlate with wet mount positivity but not symptomatology in pregnant patients infected with Trichomonas vaginalis. (In preparation 1996)

French JI, McGregor JA, Oleen-Burkey M, Magid D, McFee J. Prevention of preterm birth related to bacterial vaginosis: An economic analysis. (In preparation 1996)

McGregor JA, Hanson J, Hillier SL, Eschenbach DA, Kreutner AK, Galask RP. Efficacy of Metrogel-VaginalTM versus oral metronidazole for treatment of bacterial vaginosis:
A randomized, single-blind, parallel comparison. (Submitted 1996)

Hanson JM, McGregor JA, Hillier SL, Eschenbach DA, Kreutner AK, Galask RP, Martens M. Metronidazole vaginal gel versus oral for the treatment of bacterial vaginosis: Results of a multi-center trial. (Submitted 1996)

McFee J, Orleans M, Lezotte DC, McGregor JA. Etiologic categories of premature birth in Denver, Colorado. (Submitted 1996)

duBouchet L, McGregor JA, Ismail M, McCormack WM. A pilot study of metronidazole vaginal gel versus oral metronidazole for the treatment of Trichomonas vaginalis vaginitis. (In press, Sex Trans Dis 1997)

French JI, McGregor JA, Parker R. Increased risks for preterm birth among African American women: effects of common reproductive tract infections and benefits of treatment. Am J Obstet Gynecol (Submitted July, 1997)

Efficacy of Zidovudine and Hyperimmune HIV Immunoglobulin for Reducing Perinatal HIV Transmission from HIV-Infected Women with Advanced Disease: Results of Pediatruc AIDS Clinical Trials Group Protocol 185. (Submitted 1998)

Journal Publications (Non-Peer Reviewed)

1. McGregor JA. Management of obstetric patients with history of herpes. Collected Letters of International Correspondence, Society of Obstetrics and Gynecology 23(18):122-125, 1982.

2. McGregor JA. Prophylaxis for sexually transmitted disease after sexual assault. Aspects of Human Sexuality, July, 1985, pg. 20-28.

3. McGregor JA. Microorganisms and arachidonic acid metabolites in preterm birth. 22 Sem
Reprod Endocrin 3(3):273-278, 1985.

4. McGregor JA, Todd JK. Toxic shock syndrome at mid-decade: A review. The Female Patient 11(6):76-91, 1986.

5. McGregor JA. New initiatives in preterm birth: Microbial-host interactions. Contemp Ob-Gyn 29:33-44, 1987.

6. McGregor JA, Todd JK. Toxic shock: still a threat. The Female Patient July 12: 32-48, 1987.

7. McGregor JA. Toxic Shock: A threat for European women. Praxis-Kurier, 25/26:1-2, 1987.

8. McGregor JA. Review of R. Galask and B. Larsen eds "Infections in Obstetrics and Gynecology." ASM Newsletter, American Society for Microbiology. pg. 28, March 1987.

9. McGregor JA. Infertility in Women: The role of infection. Perspec-tives & Problems in Ob-Gyn 3(1):2-13, 1987.

10. McGregor JA. Symposium Highlight Bulletin: Treatment and Prophylac-tic Consideration in OB/GYN Infections. Scientific Therapeutic Infor-ma-tion Inc. and Section Gynecology University of Chicago, June 15, 1987.

11. McGregor JA. Preventing preterm birth caused by infection. Contemporary OB/GYN, 33-44, April 1987.

12. McGregor JA. Prevention of Preterm Birth: New Initiatives Based on Microbial-host Interactions. Obstet Gynecol Surv 43:1-14, 1988.

13. Mercer LJ, Faro S, Fortunato SJ, McGregor JA, Soper DE. Panel: In-fections in Pregnancy and the Puerperium. J Reprod Med 33(1):109, 1988.

14. Mercer LJ, Faro S, Hemsell DL, McGregor JA, Soper LJ. Panel: Pelvic Inflammatory Disease. J Reprod Med 33(1):142, 1988.

15. McGregor JA. Persistent excessive vaginal discharge. Medical Aspects of Human Sexuality. 22(4):76-7, 1988.

16. McGregor JA. Chlamydial infection in women. Obstet Gynecol Clin N Am 16(3): 565-592, 1989.

17. McGregor JA, French JI, Spencer NE. Prevention of sexually transmitted diseases in women. Obstet Gynecol Clin N Am 16(3):679-702, 1989.

18. McGregor JA. Trichomonas: A common challenge in STD treatment. STD Bull 8(6):1-11, 1989.

19. McGregor JA, French J, Schoonmaker J, Richter R, Lawellin D, Todd J. New approaches to prevention of preterm birth: cervico/vaginal microorganisms and maternal host responses. International Meeting of ESIDOG, Infectious Diseases in Obstetrics and Gynecology, Gardone Riviera, 1990.

20. McGregor JA, French JI, McKinney PJ, Milligan K. Comparison of single-dose ceftizoxime with multi-dose cefoxitin chemoprophylaxis for patients undergoing hysterectomy. Clin Therap 12 (C), 1990.

21. Seo K, McGregor JA, French JI. Infection and premature rupture of the membranes. Fetal Medicine Rev 2:1-19, 1990.

22. McGregor JA. Cervicitis and urethritis in adolescents. Infections in Medicine 24:40, 1990.

23. McGregor JA. Pathophysiology of vulvovaginal candidiasis. Journal of Clin Practice in Sexuality. Proceedings of Symposium November 3-4, 1990, Tampa, Florida.

24. McGregor JA. Ticarcillin/Clavulanate for the Treatment of Female Genital Tract Infections: Efficacy, Safety and Comparative Microbiology. J Reprod Med 35(Supplement 3):333-338, 1990.

25. McGregor JA, Lawellin D, Franco-Buff A, Todd JK. Phospholipase C activity in microorganisms associated with reproductive tract infection. Ob Gyn Digest 8:19-20, 1991.

26. Witkin S, McGregor JA. Infection-Induced Activation of Cell-Mediated Immunity: Possible Mechanism for Preterm Birth. In Clinical Obstetrics and Gynecology JB Lippincott, Philadelphia, PA, Volume 34(1):112-121, 1991.

27. White M, McGregor JA. Update on oral contraceptives. Drug Therapy, November 58-69, 1991.

28. Madinger NE, McGregor JA. Varicella during pregnancy. Contemporary Ob/Gyn 37:83-88, 1992.

29. McGregor JA. Preterm birth, premature rupture of membranes, and cervical incompetence. Current Opinion in Obstet Gynecol. 4(1):37-42, 1992.

30. Heine RP, McGregor JA. Quinolones in the gynecologic setting. The Female Patient, 17:31-37, 1992.

31. McGregor JA, French JI. Use of antibiotics for preterm premature rupture of membranes
Rationales and results. Obstet Gynecol Clin North Am 19(2):327-38, 1992.

32. McGregor JA. A Patient's Primer on Bacterial Vaginosis. OBG Management, February, 1993.

33. McGregor JA. Bacterial Vaginosis: Screening and Treatment. The Female Patient 18:81-88, 1993.

34. Lindsay G, McGregor J. Herpes and Delivery. Ask the Perinatologist, December 1993.

35. Heine P, McGregor J. Utilidad de las quinolonas en el medio ginecologico. Infectologia, August 1993.

36. Heine P, McGregor J. Trichomonas vaginalis: A re-emerging pathogen. Clin Obstet Gynecol 36(1):137-44, 1993.

37. McGregor, JA. Prevention of Rubella: Missed Opportunities. Inf Cont and Hosp Epid 14(9):1-2, 1993.

38. Madinger NE, McGregor JA, McKinney PJ, Dembeck ST, Haskell CS, Johnson Z. Comparative antibiotic susceptibilities of anaerobes associated with infections of the female reproductive tract. Clin Infect Dis. 16 Suppl 4: S349-52, 1993.

39. Gibbs RS, McGregor JA, Mead PB, Eschenbach DA, Hager WD, Sweet RL. A survey of practices in infectious diseases by obstetrician-gynecologists. Obstet Gynecol 83(4):631-636, 1994.

40. Howe J, McGregor J. Pregnancy and HIV Prevention: Unfulfilled promises. Fertility Control Reviews, September 3(3):18-22, 1994.

41. McGregor JA. Preserving Reproductive Health: Preventing PID. Genitourinary Infections in Women: Update on Urinary Tract Infections and Pelvic Inflammatory Disease. Consensus Conference Proceedings. University of Wisconsin Med School, 23-7, 1994.

42. Novy MJ, McGregor JA, Iams JD. New Perspectives on the Prevention of Extreme Prematurity. Clin Obstet Gynecol, 38(4):790-808, 1995.

43. McGregor JA. Premature birth reduced by 50 percent. Commerce City Beacon. December 13, 1995.

44. French JI, McGregor JA. Pathobiology of premature rupture of membranes. Seminars in Perinatology. 20(5): 334-68, 1996.

45. McGregor JA. New antimicrobials in obstetric and gynecologic care. OBG Management. p. 9-12, 1996.

46. McGregor JA, French JI. Opportunities and obligations for preventing preterm birth. Medical Tribune Opinion. June 20, 1996.

47. McGregor JA, Moderator CM, Hugh RK, Barber MD, Harris B, LaGuardia K, Menard MK, Mostow SR, Nolan T. Antibiotics: Minimizing the risk of drug resistance in the OB/GYN setting. The Female Patient 21:87-105, 1996.

48. McGregor JA. Bacterial vaginosis in pregnancy. Medical News. Family Circle p. 64, July 16, 1996.

49. McGregor JA, French JI, Witkin S. Infection and prematurity: evidence-based approaches. Current Opinion Obstet Gynecol 8:428-432, 1996.

50. McGregor JA. Triphasic birth control pills are safest because they deliver lower doses of estrogen by weight to the body than earlier versions of the Pill. Bottom Line Personal, February 1, 1997.

51. McGregor JA. Infection and prematurity: the evidence is in. Medical Tribune Opinion, February 6, 1997.

52. McGregor JA. Cases in clinical confidence: Unasyn® in Endometritis; case history series. Pocket reference guide. (sponsored by Pfizer) April, 1997.

53. McGregor JA, Mead PB, Hillier SL, McDonald H, Sweet RL. Screening for lower genital tract pathogens in the OB patient. Contemporary OB/GYN, May, 1997.

54. McGregor JA. Time and parturition. Preterm Labor Special Interest Group report in Society of Perinatal Obstetricians newsletter, June 1997.

55. McGregor JA, French JI. Infection and Prematurity: Evidence-based Approaches, 1997. Expert Medical Opinion, 5:1, January 1998.

56. McGregor JA. Treating BV, Infections to Prevent Preterm Delivery. OBG Management,
March 1998.

57. McGregor J. Barber H, Harris Jr. B, LaGuardia K, Menard MK, Mostow SR, Nolan T. Antibiotics-Minimizing the Risk of Drug Resistance in the OB/GYN Setting. The Female Patient. Sep 1996 Vol. 21

Correspondence:

1. McGregor JA. Human life. JAMA 247(16):2230, 1982.

2. McGregor JA, Pont A. Contraindication of ketoconazole in pregnancy. Am J Obstet Gynecol 150:793, 1984.

3. McGregor JA, Johnson S. "Fig leaf" ferning and positive nitrazine testing: Semen as a cause of misdiagnosis of premature rupture of membranes. Am J Obstet Gynecol 151(8):1142-1143, 1985.

4. McGregor JA. Prophylactic antibiotics unjustified for unselected abortion patients. Am J Obstet Gynecol 152:722, 1985.

5. McGregor JA. Dalkon Shield. Wall Street Journal, January 29, 1986.

6. McGregor JA, Levin MJ, Masters B. Lack of effect of two calcium channel blockers (lodoxamide and verapamil) on an-timicrobial action in vitro. J Infect Dis 154(3): 239-240, 1986.

7. Arlen J, McGregor J. Precocious cervical ripening and preterm labor. Obstet Gynecol 68(6):875,1986.

8. McGregor JA. Answers for STDs. Denver Post, November 11, 1986.

9. McGregor JA. Treatment of STDs No Simple Matter. Denver Post, November 20, 1986.

10. McGregor JA, French JI, Lawellin D. Amniotic fluid trypsin and PROM. Amer J Obstet Gynecol 457(5):1316-1320, 1987.

11. McGregor JA, Ellison R III. You, me, and microbe makes three. JAMA October 2, 1987.

12. McGregor JA. Enhanced bleeding with cefoxitin or moxalactam: statistical analysis within a defined population of 1493 pts. Arch Intern Med Oct. 147(10):1859, 1987

13. McGregor JA. Effect on birthweight of erythromycin treatment of pregnant women. Obstet Gynecol 71, 144-145, 1988.

14. McGregor JA. Are Neonatal Scalp Abscesses Another Complication of Bacterial Vaginosis? Ped Infect Dis J 7(6):437-438, 1988.

15. McGregor JA, Levin MJ. Reply of Screening of Varicella-Zoster Immunity and the Use of Varicella Zoster Immune Globulin in Pregnancy.

16. McGregor JA, Leff M. Does maternal genital herpes infection influence fetal gender? Am J Obstet Gynecol 162(5):1346-7, 1990.

17. McGregor JA. The Wart Lady of Kansas. J of the Royal Society of Medicine 85:307, 1992.

18. McGregor JA. "Prolife" perinatologist. N Engl J Med 327(11):813-4, 1992.

19. McGregor JA, Paul KC. Abortion and euthanasia. Lancet 342 (8886-8887):1557-8, 1993.

20. McGregor JA, French JI. Bacterial vaginosis and preterm birth. N Engl J Med 334(20):1337-38, 1996.

21. McGregor JA, French JI. Preterm premature rupture of membranes. Lancet 347(8995): 203-4, 1996.

22. McGregor JA, French JI. Evaluation of preterm birth misleading (response). Am J Obstet Gynecol 174(4):1392, 1996.

23. Braddy K, McGregor JA. Ten classical concepts for modern medical practice. Am J Obstet Gynecol 175(2), 503-504, 1996.

24. McGregor JA, French JI. Questions for the study of infections and preterm labor. Am J Obstet Gynecol 175(3, pt. 1), 754, 1996.

25. McGregor JA. Chlamydia. You get it by having sex. You may not know you have it. It can make you infertile. The Washington Post, June 24, 1997.

Book Chapters

1. McGregor JA. Dilatation and Curettage. In Prognosis of Surgical Disease. Eiseman B (ed), WB Saunders Co., Philadel-phia, PA, 1980.

2. McGregor JA, Neifert MR. Maternal Problems in Lactation. In Lactation: Physiology, Nutrition and Breast Feeding. Neville M, Neifert M (eds)., Plenum Press, 1983. Winner of the "Award for Excellence," in The Life Sciences Profes-sional and Scholar-ly Publishing Division. Associates of American Publishers, 1983.

3. McGregor JA. Lactation and Contraception. In Lactation: Physiology, Nutrition and Breast Feeding. Neville M, Neifert M (eds)., Plenum Press, 1983. Winner of the "Award for Excel-lence," in The Life Sciences Professional and Scholarly Publish-ing Division. Associates of American Publishers, l983.

4. McGregor JA, Harris T. Perinatal Infections. In Obstetric, Neona-tal, and Gynecologic Care. Haffner W, Harris T (eds), American Col-lege of Obstetricians and Gynecologists, Washington, D.C., 1983, p. 101-134.

5. McGregor JA, Wall RE, LaForce M. Infectious Diseases. In Medical Problems in Pregnancy. Abrams R, Wexler P (eds)., Little Brown, 1984.

6. McGregor JA. Toxic Shock Syndrome. In Gynecology and Obstetrics. Sciarra J (ed), Harper Row, Philadelphia, 1986.

7. McGregor JA. Prevention and Treatment of Congenital Syphilis. In The Periodic Health Exam in Primary Care. Hudson W (ed), Little, Brown, 1987.

8. McGregor JA. Maternal and Perinatal Prevention of Viral Hepatitis. In The Periodic Health Exam in Primary Care. Hudson W (ed), Lit-tle, Brown, 1987.

9. McGregor JA. Prevention of Tuberculosis in Pregnant Women and Their Progeny. In The Periodic Health Exam in Primary Care. Hudson W (ed), Little, Brown, 1987.

10. McGregor JA. Toxoplasmosis and Pregnancy. Chapter 19. In The Periodic Health Exam in Primary Care: Health Promotion and Disease Prevention. Hudson TW, Stewart GK, Rinhart MA, Rose SD (eds), Little, Brown, and Company l987.

11. McGregor JA. Viral Hepatitis. Chapter 21. In The Periodic Health Exam in Primary Care: Health Promotion and Disease Preven-tion. Hudson TW, Stewart GK, Reinhart MA, Rose SD (eds), Little, Brown, and Company l987.

12. Mathias MM, Tsai A, Harris M, McGregor JA. Oral Administration of Menhaden Oil Alters Gestation in Rats. In Polyunsaturated Fatty Acids and Eicosanoids. W.E.M. Lands, Ed., AOCS, 1987.

13. McGregor JA. Gynecologic Infections. (Section Author) PROLOG; American College of Obstetricians and Gynecologists, 1988.

14. Clinical Preventive Medicine: Health Promotion and Disease Prevention. Hudson TW, Reinhart MA, Rose SD, Stewart GK (eds). Little, Brown, and Company, 1988.

15. McGregor JA. Toxic Shock Syndrome: The Basis for Treatment. In Drug Therapy in Gynecologic Infections. Hemsell Marcel Dekker, Inc. 1988.

16. McGregor JA. Cervicitis and Urethritis in Adolescents In Adolescent Gynecology. K Kreutner (ed). Little Brown.

17. French JI, McGregor JA. Infectious Disease Complications in Pregnancy. Chapter 25 In Maternal and Infant Care Nursing 3rd Edition McGraw-Hill Company, New York, New York 1990.

18. McGregor JA, Madinger NE. Varicella-zoster infection in pregnancy. Chapter 20 In Infections in Obstetrics and Gynecology, Mead P, Hager WD, eds. 1991.

19. Schoonmaker JN, James JF, Lunt BD, Jones WM, French JI, DW Lawellin, McGregor JA. Protease and Antiprotease Interactions in Bacterially Mediated Rupture of Fetal Membranes. Chapter 29 In The Extracellular Matrix of the Uterus, Cervix and Fetal Membranes: Synthesis, Degradation and Hormonal Regulation, Leppert PC (ed), Woessner JF (ed). Perinatology Press Ithaca, New York 1991:263-273.

20. Seo K, McGregor JA, French JI. Infection in Premature Rupture of the Membranes. Chapter 53. In Management of High-Risk Pregnancy, Queenan JT, ed. 1993.

21. McGregor, JA. Study Guide for Textbook of Gynecology, Associate Editor. WB Saunders Company, 1993.

22. McGregor, JA. Family Planning and STDs/HIV In Fertility Control 2nd Edition. Golden Publishers. Corson SL, Derman RJ, Tyrer LB, eds. London, Ont., Canada, 1994.

23. McGregor, JA. HIV-1 Infection in Women. Chapter 37 In Principles and Practice of Obstetric Analgesia and Anesthesia 2nd Edition. Waverly Company, USA, 1995

24. McGregor JA. Toxic Shock Syndrome. Chapter 43 In Gynecology and Obstetrics, Revised edition 1995. Sciarra, JJ (ed). JB Lippincott Company, Philadelphia, PA 1995.

25. McGregor JA. Human Papilloma Virus In TSI 1996 Yearbook: Continuing Medical Education for Healtcare Workers. Ledward RS, Grudzinskas G, Keith L (ed). ISIS Medical Media Ltd., Oxford, UK 1996.

26. Christian SS, Christian JA, McGregor JA. Return to Ativity Postpartum In The Female Athlete. Ireland ML, Blackwell, Science, 1996.

26. Thompson LC, McGregor JA. Vulvovaginitis In Conn's Current Therapy 1997. Rakel RE, ed. WB Saunders Company, Philadelphia, PA, 1997.

27. McGregor JA. Herpes Genitalis In OB/GYN Secrets 2nd Edition. Frederickson HL, Wilkins-Haug L, eds. Hanley & Belfus, Inc., Philadelphia, PA, 1997.

28. McGregor JA. Infections During Pregnancy In OB/GYN Secrets 2nd Edition. Frederickson HL, Wilkins-Haug L, eds. Hanley & Belfus, Inc., Philadelphia, PA, 1997.

Submitted for Publication

French JI, McGregor JA. Bacterial Vaginosis: Pathogenic factors and preterm birth In Sexually Transmitted Diseases: Epidemiology, pathology, diagnosis, and treatment. Borchardt KA, Maida N (eds). CRC Press, Inc. (In press, 1996)

French JI, McGregor JA. Bacterial Vaginosis in Pregnancy: Pathobiology and Prevention of Associated Complications In Maternal Fetal Medicine. Nugyen H, Hobbins JC (eds). (In Press, 1996).

Thompson LC, McGregor JA. Vaginitis and Sexually Transmitted Diseases In Gynecology For the Practicing Internist. Charney P, Ryden J, Bienstock J (eds). (In Press, 1997).

Monographs

1. McGregor JA. New Initiatives in Preventing Preterm Delivery. Robert Wood Johnson Foundation, 1986.

2. McGregor JA. Preservation of Fertility. United States Congress, Office of Technological Assessment, (OTA) 1987. ($8,000 grant)

3. Faro S, McGregor JA, Soper DE. Antibiotic Choices in Obstetrics and Gynecology. American College of Obstetricians and Gynecologists, 1992.

4. LaGuardia K, Hillier S, McGregor JA, Ferris D, Nelson A, Martin D, Carey C, Schwebke J, Farkas D. Contemporary Perspectives in Vaginal Infection and Health, 1993.

5. McGregor JA. A Patient's Primer on Bacterial Vaginosis. OBG Management, February 1993.

6. McGregor JA. Systemic Versus Topical Antifungal Treatment. Clinician 12(5):16-19, 1994.

7. McGregor JA. Preserving Reproductive Health: Preventing PID. Consensus conference proceedings, Genitourinary Infections in Women: Update on Urinary Tract Infections and Pelvic Inflammatory Disease (sponsored byOrtho-McNeil Pharmaceutical), 1994.

8. McGregor JA. The new paradigm in women's health: Advances in diagnosis and management of sexually transmitted diseases. New Paradigms in Women's Health: STD, PID, HIV. (sponsored by Pfizer, Inc.) July, 1996.

9. McGregor JA. A management update for clinicians: Screening, diagnosing and treating the patient with Chlamydia trachomatis infection. (sponsored by Pfizer, Inc.) June, 1997.

Abstracts

1. Bernard B, Pressley M, Roualt C, McGregor JA. Intervention of Rh-isosensitization in the neonate. National Neonatology Con-ference, June, 1977.

2. Bernard B, Pressley M, Roualt C, McGregor JA. Intrauterine or intrapartum Rh-isosensitization and use of micro-rhogam in the neonate. Clin Res 26:1978.

3. Bernard B, Pressley M, Roualt C, McGregor JA. Intrauterine or intrapartum Rh-isosensitization and use of micro-rhogam in the neonate. Pediatric Research 579:460, 1978.

4. Bernard B, Pressley M, Gruenhage J, McGregor JA. Evaluation of micro-rhogam in Rh-negative neonates. Pediatric Research 10:374, 1976; St. Louis, August, 1978.

5. Chilmonczyk BA, Levin MJ, McGregor JA, Hayward AR. Maturity of newborn monocyte processing of herpes virus antigens. Pediatric Research, Carmel, California, February, 1983.

6. McGregor JA, Burns J, Spencer N. Transplacental transmission of T. pallidum after "adequate therapy." International Society for S.T.D. Research, Seattle, Washington, August 1-3, 1983.

7. McGregor JA, Reller LB, Merrit S, Broersma S. Antimicrobial proper-ties of substances used in collection of microbiologic samples obtained by cul-docentesis. International Society for S.T.D. Research, Seattle, Washington, August 1-3, 1983.

8. McGregor JA, Klaich L, Clark J. Atypical presentation of geni-tal mollus-cum contagiosum. International Society for S.T.D. Research, Seattle, Washington, August 1-3, 1983.

9. Allen-Davis JT, Parker R, McGregor JA, Beck A, McClatchey, MW. Assessment of vulvovaginal complaints: agreement between phone and office management. Primary Care Update for OB/GYNS, 5:4, July/August 1998.

10. McGregor JA, Reller LB, Merrit S, Broersma S. Antimicrobial proper-ties of substances used in collection of microbiologic samples obtained by cul-docentesis. American College of Obstetricians and Gynecologists, Monterey, California, October 12-15, 1983

11. McGregor JA, Libby J, Judson F. Sexually transmitted diseases evaluation and consideration for prophylaxis after sexual assault. American College of Obstetricians and Gynecologists, Monterey, Califor-nia, October 12-15, 1983.

12. McGregor JA, Lawellin D., Franco-Buff A, Todd JK, Makowski E. Phospholipase A2 activity in vaginal microflora. IV Interna-tional Washington Spring Symposium, Prostaglandins and Leukotrienes '84, Washington, D.C., May 8-11, 1984.

13. Spencer N, McGregor JA, Yoritomo M, Barr R. Evaluation of estradiol, progesterone, and ethyl alcohol on interpretation of blinded, replicate VDRL and FTA testing. International Conjoint S.T.D. Meeting, Montreal, Canada, June 17-21, 1984.

14. McGregor JA. Iatrogenic "autoinoculation" of genital herpes simplex virus. International Conjoint S.T.D. Meeting, Montreal, Canada, June 17-21, 1984.

15. McGregor JA, Dillon M. Laparoscopically confirmed acute salpingitis associated with acute primary genital herpes simplex virus infection. International Conjoint S.T.D. Meet-ing, Montreal, Canada, June 17-21, 1984.

16. McGregor JA, Spencer N, Dillon BA. Psychosexual attitudes and behavioral risk factors for acute salpingitis. Intern'l Conjoint S.T.D. Meeting, Montreal, Canada, June 17-21, 1984.

17. McGregor JA, Lawellin D, Franco-Buff A, Todd JK. Phos-pholipase C production by microor-ganisms associated with necrotizing fasciitis. ICAAC, Washington, D.C., October 8-10, 1984.

18. McGregor JA, French JI, Spencer N, Reller LB:. Randomized, prospective, double-blinded trial of erythromycin base in preterm labor. ICAAC, Washington, D.C., October 8-10, 1984.

19. McGregor JA, Spencer NE, French JI, Christensen F, Spiegel J, Baron A, Judson FN. Psychosexual and behavioral risk fac-tors for acute salpingitis. 22nd Annual Association of Planned Parenthood Professionals, San Antonio, Texas, Novem-ber, 1984.

20. McGregor JA, Lawellin D, Franco-Buff A, Todd JK. Demonstra-tion of specific and nonspecific protease production by microor-ganisms associated with necrotizing fasciitis. American Society for Microbiology Annual Meeting, 1985.

21. Lawellin D, Kishiyama J, Carson J, McGregor JA, Todd J. Forma-tion of arachidonic acid metabolites by cervical/vaginal microorganisms. American Society for Microbiology Annual Meeting, 1985.

22. McGregor JA, Lawellin D, Franco-Buff A, Todd JK, Makowski EL. Phospholipase A2 activity of genital tract micro flora detected with two substrates. Society for Gynecologic Inves-tigation, Phoenix, Arizona, March 20-23, 1985.

23. McGregor JA, Lawellin D, Franco-Buff A, Vasil M, Todd JK. Phospholipase C production by microorganisms associated with female upper genital tract infection. Society for Gynecologic Inves-tigation, Phoenix, Arizona, March 20-23, 1985.

24. Lawellin D, Kishiyama J, Carson J, McGregor JA, Todd J. Forma-tion of arachidonic acid metabolites by cervical/vaginal microorganisms. Society for Gynecologic Investigation, Phoenix, Arizona, March 20-23, 1985.

25. McGregor JA, French JI, Franco-Buff A, Todd JK. Chorioam-niotic tensile strength alteration induced by protease-producing microor-ganisms. Society for Gynecologic Investigation (abstract accepted for publication), Phoenix, Arizona, March 20-23, 1985.

26. McGregor JA, Spencer NE, French JI, Christensen F, Baron A, Judson FN. Psychosexual and behavioral risk factors for acute salpin-gitis. International Society for S.T.D. Research, Brighton, England, July 31-August 2, 1985.

27. McGregor JA, Levin M, Masters H. Evaluation of two calcium blocker (lodoxamide and verapamil) on in vitro antimicrobial action. ICAAC, Minneapolis, Minnesota, September 29-October 2, 1985.

28. McGregor JA, French JI. Microorganisms from the uterine and abdominal wound sites in cesarean sections. ICAAC, Min-neapolis, Min-nesota, September 29-October 2, 1985.

29. McGregor JA, French JI, Reller LB, Todd JK, Makowski EL. Adjunctive erythromycin treatment for idiopathic preterm labor: Results of a randomized, double-blinded, placebo-controlled trial. Central Association of Obstetricians and Gynecologists, New Orleans, Louisiana, October 10-12, 1985.

30. McGregor JA. Prophylactic antibiotics unjustified for un-selected abortion patients. Association of Planned Paren-thood Profes-sionals, Seattle, Washington, October 17-19, 1985.

31. McGregor JA, Lawellin D, Franco-Buff A, Todd JK. Demonstra-tion of phospholipase A2 (PLA2) production by microor-ganisms as-sociated with necrotizing fasciitis. Infectious Diseases Society for Obstetrics and Gynecology, Vancouver, August 8-10, 1985.

32. McGregor JA, McFarren TC, Huff C. Fibronectin localization in the lower genital tract. Infectious Disease Society for Obstetrics and Gynecology, Vancouver, August 8-10, 1985.

33. McGregor JA, Lawellin D, Franco-Buff A, Todd JK, Makowski EL. Mucinase (neuraminidase) production in microorganisms as-sociated with upper genital tract infection. Society for Gynecologic Inves-tigation, Toronto, Ontario, Canada, March 19-22, 1986.

34. McGregor JA, Lawellin D, Schroeter U, Todd JK, Makowski EL. IgA protease activity in microorganisms associated with upper genital tract infection determined by ELISA. Society for Gynecologic Inves-tigation, Toronto, Ontario, Canada, March 19-22, 1986.

35. McGregor JA, Lawellin D, Franco-Buff A, Todd JK, Makowski EL. Mucinase (neuraminidase) production in microorganisms as-sociated with upper genital tract infection. American Society for Microbiol-ogy, Washington, D.C., March 23-28, 1986.

36. McGregor JA, Lawellin D, Schroeter U, Todd JK, Makowski EL. IgA protease activity in microorganisms associated with upper genital tract infection determined by ELISA. American Society for Microbiology, Washington, D.C., March 23-28, 1986.

37. French JI, Magilvy JK, Spencer NE, Roberts J, McGregor JA, Chris-ten-sen F. Investigation of the multidimensional health locus of control scale in women with pelvic inflammatory disease. American College of Nurse-Midwives, April 20-24, 1986, Portland, Oregon.

38. Richter R, Christensen F, Finn J, French JI, Vuchtetich M, McGregor JA. Vaginal/cervical bacterial virulence factors and preterm labor. American College of Nurse-Midwives, April 20-24, 1986, Portland, Oregon.

39. McGregor JA, French JI, Franco-Buff A, Todd JK. Collagenase-producing cervical/vaginal microorganisms reduce tensile strength of chorioamniotic membranes. 34th Annual Meeting American Col-lege of Obstetricians and Gynecologists, New Orleans, LA, May 5-8, 1986 (2nd Prize Paper).

40. McGregor JA, French JI, Lawellin D, Franco-Buff A, Todd JK. Putative host-microbial interactions in the pathogenesis of premature labor and premature rupture of membranes (PROM). XVIII International Con-gress of Pediatrics, Honolulu, Hawaii, July 7-12, 1986.

41. McGregor JA, Ugol J, French J, Haverkamp A. Electronic fetal monitoring (EFM) in the septic perinate. Infectious Disease Society for Obstetrics and Gynecology, Boston, MA, August 6-9, 1986.

42. McGregor JA, Crawford G, Levin M. Fluorescent antibody membrane antigen (FAMA) testing in evaluation of maternal varicella exposure. Infectious Disease Society for Obstetrics and Gynecol-ogy, Boston, MA, August 6-9, 1986.

43. McGregor JA, Richter R, Christensen F, Lawellin D, Todd JK. Cervical/vaginal microbiologic influences and perinatal morbidity. ICAAC, New Orleans, LA, Sept. 28-Oct. 1, 1986.

44. McGregor JA, French JI, Richter R, Lazotte D, Rickard R, Christensen F, Orleans M. Prospective assessment of selected mater-nal microbiological, obstetrical, and behavioral attributes and preterm delivery. 6th Annual Epidemiological Research Exchange, UCHSC, Denver, CO, October 23, 1986.

45. McGregor JA, Reller LB, French JI, Christensen F, Johnson Z. Evalua-tion of Imipenem (IM) Ticarcillin/Clavulanic acid (TM), Ticarcillin (TI), Cefotetan (CT) and Cefoxitin (CX) MICs for upper genital tract isolates. American Society for Microbiology, Atlan-ta Georgia, March 1-4, 1987.

46. McGregor JA, French JI, Lawellin D, Franco-Buff A, Todd JK. Reduction of Amniochorion (AC) strength and elasticity by polymor-phonuclear (PMN) lysate. Society for Gynecologic Investiga-tion, 34th Annual Meeting, March 18-21, 1987, Atlanta, Georgia.

47. McGregor JA. Toxic Shock Syndrome. International Society for Infectious Diseases in Ob/Gyn, Munich Germany, March 4-6, 1987.

48. French JI, McGregor JA, Lawellin D, Franco-Buff A, Todd JK, Smith C. In vitro reduction in fetal membrane strength in-duced by microor-ganisms. Presented: American College of Nurse-Midwives 32nd Annual Conven-tion, May 1 - 7, 1987, Orlando, Florida.

49. Richter R, McGregor JA, French JI, Vuchetich M, Christensen F, Finn J. Vaginal/cervical bacterial virulence factors and preterm labor. Presented: American College of Nurse-Midwives 32nd Annual Convention, May 1-7, 1987, Orlando, Florida.

50. McGregor JA, Ellison RT III. Streptococcal sex syndrome: recurrent post-coital streptococcal erythroderma in women. Ac-cepted for presenta-tion, Association of Planned Parenthood Professionals Annual Meeting, April 30 - May 2, 1987, Las Vegas, Nevada.

51. French JI, McGregor JA, Lawellin D, Franco-Buff A, Todd JK. Exploring the role of microor-ganisms in preterm labor. Twelfth National Primary Care Nurse Practitioner Symposium, Keystone, Colorado, July 17-20, 1987.

52. McGregor JA, French JI, Lawellin DA, Franco-Buff A, Richter R, Christensen F, Todd JK. Aspects of Cervical/vaginal microorganisms and maternal host defense in the pathogenesis of preterm labor and birth. International Society for STD Research, 7th International meeting, Atlanta, Georgia, August 2-5, 1987.

53. McGregor JA, French JI, Richter R, Hillier S, Christensen F, Lawellin DA, Franco-Buff A, Todd JK. Preterm birth and cervico/vaginal microbiological-host interactions. Interna-tional Society for STD Research, 7th International meeting, Atlan-ta, Georgia, August 2-5, 1987.

54. McGregor JA, French JI, Lawellin DA, Franco-Buff A, Richter R, Christensen F, Todd JK. Aspects of cervical/vaginal microorganisms and maternal-host defense in the pathogenesis of premature labor and birth. The New York Academy of Sciences Conference on: Impact on the Fetus of Parental Sexually Transmitted Diseases. Arlington, Virginia, September 28-20, 1987.

55. French JI, McGregor JA, Lawellin DA, Todd JK. Role of microor-ganisms in preterm delivery. Armed Forces District ACOG/NAACOG Annual Conference. Denver, Colorado, October 4-9, 1987.

56. Vuchetich M, McGregor JA, French JI, Richter R, Hillier S, Christensen F, Lawellin DA, Franco-Buff A, Todd JK. Preterm birth and cervico/vaginal microbiologic-host interactions. Nurses Association of the American College of Obstetricians and Gynecologists, Atlanta, Georgia, November, 1987.

57. McGregor JA, Gordon SF, Krotec J, Poindexter AN. Results of a randomized, multi-center, comparative study of a single dose of cefotetan vs. multi-doses of cefoxitin as prophylaxis in Cesarean Sections. Efficacy and Cost Implications of the New Cephalosporins, August 21-22, 1987, Vancouver, British Columbia.

58. McGregor JA, Ellison RT III. Streptococcal Sex-Syndrome: Recurrent Post-coital Lower Extremity Streptococcal Erythroderma in Women. American College of Obstetrics and Gynecology, Hyatt Regency Hotel, San Francisco, California, August 30-September 2, 1987.

59. Berkeley AS, Freedman KS, Hirsch JC, Ledger WJ, Benigno BB, Galask RP, Gordon SF, McGregor JA, Orr JW, Sevin BC. Com-parison of Cefotetan and Cefoxitin prophylaxis for Abdominal and Vaginal Hysterectomy.

60. Galask RP, Benigno BB, Cunningham FG, Elliot JP, McGregor JA, Poindexter AN. Results of a Multi-center Comparative Study of Single Dose Cefotetan and Multi-dose Cefoxitin as Prophylaxis in Cesarean Sections.

61. McGregor, JA. Treatment of Obstetrical and Gynecologic Infections with Emphasis on Beta-Lactamase Producing Organisms. Beta-Lactamase Inhibition: Therapeutic Implications in Obstetrics and Gynecology, November 12-15, 1987, Phoenix, Arizona.

62. McGregor JA, Lovell GL, Soper D. Clostridia sordelli mediated toxic shock and myonecrosis. American Society for Microbiologists, Miami Beach Florida, May 8-13, 1988.

63. McGregor JA, Schoonmaker JN, French JI, Lawellin D, Todd JK. Impairment of amniochorion (AC) strength, elasticity, and work to rupture by neutrophils, lymphocytes, and leukocyte elastase. Society for Gynecologic Investigation, Hyatt Regency Hotel, Baltimore, Maryland, March 17-20, 1988.

64. McGregor JA, French JI, Richter R, Christensen F, Hillier S, Lawellin D, Franco-Buff A, Todd JK. Cervical-vaginal microbial-host interac-tion and maternal and perinatal outcomes: Refining the hypothesis. Society for Gynecologic Investigation, Hyatt Regency Hotel, Baltimore, Maryland, March 17-20, 1988.

65. McGregor JA, French JI, Richter R, Vuchetich M, Bachus V, Franco-Buff A, Hillier S, Todd JK. Prospective, double-blinded, randomized placebo-controlled trial for short-course erythromycin (E) base in women at high risk for preterm birth. Society for Gynecologic Investigation, Hyatt Regency Hotel, Baltimore, Maryland, March 17-20, 1988.

66. McGregor JA, Schoonmaker JN, French JI, Lawellin D, Todd JK, Makowski EL. Leukocyte-mediated fetal membrane impairment: A pathophysiologic mechanism of premature rupture of membranes (PROM)? Society of Perinatal Obstetricians, Caesar's Palace, Las Vegas, Nevada, February 3-6, 1988.

67. McGregor JA, Wood LA, Harris M, Mathias M, Makowski EL. Influence of dietary lipids in preterm labor: A case-controlled study. Society of Perinatal Obstetricians, Caesar's Palace, Las Vegas, Nevada, February 3-6, 1988.

68. McGregor JA, French JI, Richter R, Christensen F, Hillier S, Lawellin D, Franco-Buff A, Todd JK, Makowski EL. A prospective evaluation of cervico/vaginal microbiologic host interaction and maternal & perinatal outcome. Society of Perinatal Obstetricians, Caesar's Palace, Las Vegas, Nevada, February 3-6, 1988.

69. Richter R, French J, Vuchetich M, Bachus V, Christensen F, McGregor JA. Double-Blinded, Prospective Study of a Defined Course of Erythromycin in Reducing Short Gestations Correlated with Lower Genital Tract Microbiologic Studies. American College of Nurse Midwives 33rd Annual Convention, April 24-27, 1988, Detroit, Michigan.

70. McGregor JA, French JI, Richter R, Christensen F, Hillier SL, Lawellin DA, Franco-Buff A, Todd JK, Makowski EL. Cervical-vaginal microbial-host interactions and maternal and perinatal outcomes: Refining the hypothesis. American College of Obstetricians and Gynecologist's 36th Annual Clinical Meeting, Boston, Massachusetts, May 2-5, 1988.

71. McGregor JA, French JI, Hillier S, Todd JK. Prevention of Preterm Birth: Results of a Double-Blinded, Randomized, Prospective, Placebo-Controlled Trial of a Short Course Clindamycin Treatment of Women with Preterm Labor. Infectious Disease Society for Obstetrics-Gynecology, August 4-7, 1988, Snowmass Village, Colorado.

72. McGregor JA, Schoonmaker J, Lunt B, Lawellin D, Todd JK. Antimicrobial Inhibition of Bacteria-Mediated Fetal Membrane Alterations. Infectious Disease Society for Obstetrics-Gynecology, August 4-7, 1988, Snowmass Village, Colorado.

73. McGregor JA, Christensen F, French JI. Intramuscular (IM) Imipemen/Cilistatin (I/C) Treatment of Women with Upper Genital Tract Infection: Efficacy, Tolerance and Cost Analysis. Infectious Disease Society for Obstetrics-Gynecology, August 4-7, 1988, Snowmass Village, Colorado.

74. McGregor JA, Soper D, Lovell GL. A Toxic Shock-Like Syndrome Caused by Clostridia sordelli Affecting Post-Partum Women. Infectious Disease Society for Obstetrics-Gynecology, August 4-7, 1988, Snowmass Village, Colorado.

75. McGregor JA, Christensen FB. Sulbactam/Ampicillin vs. Clindamycin/Gentamicin in the Treatment of Postpartum Infections. 12th World Congress of Gynecology and Obstetrics, Rio de Janeiro, October 22-29, 1988.

76. McGregor JA, French J, Richter R, Lawellin D, Todd J. Cervico-vaginal microbial-host interaction and maternal and perinatal outcome: Refining the hypothesis. ACOG District 8-9 Annual Meeting, Palm Desert, CA October 1-4, 1988. (First Prize Paper Award)

77. McGregor JA, French JI. Double-Blind, Randomized, Placebo Controlled, Prospective Evaluation of the Efficacy of Short Course Erythromycin in Prolonging Gestation Among Women with Preterm Rupture of Membranes. Interscience Conference on Antimicrobial Agents and Chemotherapy, Los Angeles, CA, October 23-26, 1988.

78. Schoonmaker JN, Lawellin DW, Lunt B, McGregor JA. Staphylococcus aureus and Human Neutrophils Weaken the amniochorionic (AC) Membrane. Interscience Conference on Antimicrobial Agents and Chemotherapy, Los Angeles, CA, October 23-26, 1988.

79. Sparks JW, Leff MG, Lezotte DC, Orleans M, McGregor JA. Prenatal Care: Graded Effects on Maternal and Newborn Outcomes. Society for Gynecologic Investigation, San Diego, CA, March 15-18, 1989.

80. Schoonmaker JN, Lunt BD, Lawellin DW, French JI, McGregor JA. Diagnosis of Bacterial Vaginosis: Comparison of the Gram Stain Method vs. Proline Aminopeptidase Assay. Society for Gynecologic Investigation, San Diego, CA, March 15-18, 1989.

81. McGregor JA, Garely AD, Lawellin DW, Lunt BD, Schoonmaker JN. Fetal Membrane Tensile Strength: Is It Impaired by Bacterial Phospholipase A2? Society for Gynecologic Investigation, San Diego, CA, March 15-18, 1989.

82. McGregor JA, Schoonmaker JN, Lawellin DW, Lunt BD. Prevention of Microbial Induced Impairment of Amniochorion by Specific Protease Inhibitor. Society of Perinatal Obstetricians, New Orleans, LA, January 31-February 4, 1989.

83. McGregor JA, French JI. Double-Blind, Randomized, Placebo Controlled, Prospective Evaluation of the Efficacy of Short Course Erythromycin in Prolonging Gestation Among Women with Preterm Rupture of Membranes. Society of Perinatal Obstetricians, New Orleans, LA, January 31-February 4, 1989.

84. McGregor JA, French JI. Efficacy of Short Course Erythromycin in Prolonging Gestation Among Women with Preterm Rupture of Membranes (PROM): Results of a Prospective Double-Blind, Randomized, Placebo Controlled Trial. American College of Obstetricians and Gynecologists, Atlanta, GA, May 22-25, 1989.

85. McGregor JA, French JI, Hillier S. Clindamycin Adjunctive Therapy for Idiopathic Preterm Labor: Results of a Double-Blind, Randomized, Prospective Placebo Controlled Trial. American College of Obstetricians and Gynecologists, Atlanta, GA, May 22-25, 1989.

86. McGregor JA. Pelvic Abscess. Association of Reproductive Health Professionals Annual Meeting. October 19-21, 1989, San Diego, CA.

87. McGregor JA, Schoonmaker JN, French JI, Lunt BD, Lawellin DW. Antibiotic inhibition of bacterial-induced fetal membrane weakening. American College of Obstetrics and Gynecologists. San Francisco, CA, May 5-10, 1990.

88. McGregor JA, Blomer A. Do membranous epithelial cells exist in the endocervix? American College of Obstetrics and Gynecology. San Francisco, CA, May 5-10, 1990.

89. McGregor JA, French JI, Schoonmaker JI, Todd J. New approaches to prevention of preterm birth: Cervico/vaginal microorganisms and maternal host responses. 2nd International Meeting of European Society for Infectious Diseases in Obstetrics and Gynecology. May 3-5, 1990, Gardone Riviera, Italy.

90. McGregor JA, Leff J. Fetal gender differences in preterm birth: A North American cohort. Society for Gynecologic Investigation March 21-24, 1990, St. Louis, MO.

91. Murphy K, McGregor JA. Analysis of variance of fetal membrane strength, elasticity, and work to rupture. Society for Gynecologic Investigation, March 21-24, 1990, St. Louis, MO.

92. McGregor JA. New Approaches to the prevention of preterm birth: Treatment of Chlamydia. Ob/Gyn Care in the 1990s. The Chlamydia Challenge. ACOG Clinical Meeting, San Francisco, CA, May 6, 1990.

93. McGregor JA, French JI. Results of a randomized, double-blinded, comparative trial of a single dose of cefoxitin vs. cefotetan as prophylaxis in cesarean section. Infectious Disease Society for Obstetrics and Gynecology August 8-11, 1990, Seattle, Washington.

94. McGregor JA, Schoonmaker JN, Jones WM, et al. Vaginal fluid mucinase and neura-minidase correlates with microbial findings during pregnancy. Interscience Conference on Antimicrobials Agents and Chemotherapy. 30th Annual Meeting, October 21-24, 1990, Atlanta, Georgia.

95. McGregor JA, French JI, Seo K. Results of a double-blind, placebo-controlled trial of clindamycin in preterm labor. Society for Perinatal Obstetricians, Abstract 38 (Plenary Session Presentation), January 28-February 2, 1991, San Francisco, CA.

96. McGregor JA, French JI, Seo K. Adjunctive clindamycin therapy for preterm labor: Results of a double-blind, placebo-controlled trial. World Congress for Infectious Diseases, Bangkok, Thailand, September 7-14, 1991.

97. French JI, Richter R, McGregor JA. Incidence of bacterial vaginosis (BV) among low income pregnant women: Association with premature rupture of membranes. ISSTDR, Banff, Alberta, Canada, October 6-9, 1991.

98. Jones W, French JI, Draper D, Richter R, McGregor JA. Vaginal wash phospholipase A2 (PLA2) is associated with bacterial vaginosis (BV) in pregnant women. ISSTDR, Banff, Alberta, Canada, October 6-9, 1991.

99. Draper D, Jones W, Richter R, James J, Todd J, McGregor JA. Effect of trichomonas vaginalis on fetal membranes bursting strength. ISSTDR, Banff, Alberta, Canada, October 6-9, 1991.

100. Draper D, Richter R, Jones W, French JI, Patterson E, Thorsgard K, McGregor JA. Incidence of trichomonas vaginalis in pregnant women. ISSTDR, Banff, Alberta, Canada, October 6-9, 1991.

101. McGregor JA, Livengood C III, French JI, Hughes C. Intravaginal metronidazole gel (0.75%) for bacterial vaginosis: results of a double-blinded, randomized, placebo-controlled trial. ISSTDR, Banff, Alberta, Canada, October 6-9, 1991.

102. McGregor JA, French JI, Draper D, Jones W, Richter R, McKinney PJ, Milligan K, Patterson E. Clindamycin vaginal cream reduces vaginal mucinase and neuraminidase in women with bacterial vaginosis (BV). IDSOG, Southampton, Bermuda, August 1-5, 1991.

103. McGregor JA, Draper D, Jones W, Schoonmaker J, James J. Trichomonas vaginalis (TV) alters chorioamniotic membrane strength. IDSOG, Southampton, Bermuda, August 1-5, 1991.

104. McGregor JA, McKinney PJ, Dunne JT, Johnston D, Warwick AS, Yuzpe A. Single dose ceftizoxime is as effective as multi-dose cefoxitin for chemoprophylaxis in abdominal and vaginal hysterectomy patients. IDSOG, Southampton, Bermuda, August 1-5, 1991.

105. McGregor JA, French JI, Schoonmaker JN, Jones W, McKinney PJ, Milligan KR, Patterson EL, Richter R, Todd JK. Vaginal fluid mucinase and neuraminidase correlates with microbial findings in 262 women during pregnancy. IDSOG, Southampton, Bermuda, August 1-5, 1991.

106. Sparks JW, McGregor JA, Leff MG, Lezotte DC, Orleans M. Prenatal care: Differential effects on maternal and neonatal outcomes. Society of Perinatal Obstetricians, Orlando, Florida, February 3-8, 1992.

107. McGregor JA, Jones W, French JI, Draper D, Richter R. Vaginal phospholipase A2 (PLA2) is associated with bacterial vaginosis in pregnant women. Society for Gynecologic Investigation, San Antonio, Texas, March 15-21, 1992.

108. Draper D, Richter R, Heine P, French JI, Jones W, McGregor JA. Trichomonas vaginalis (T. vag) proteases impair human fetal membrane strength. American Society for Microbiology, New Orleans, Louisiana, May, 1992

109. Heyborne K, McGregor JA, Witkin S, Henry G. Tumor necrosis factor alpha (TNF-a) in second trimester amniotic fluid is associated with impaired intrauterine fetal growth. Society of Perinatal Obstetricians, Orlando, Florida, February 3-8, 1992.

110. Silver R, McGregor JA. Interleukin-six levels in amniotic fluid in normal and abnormal pregnancies. Society for Perinatal Obstetricians, Orlando, Florida, February 3-8, 1992.

111. McGregor JA, McKinney PJ. Temafloxacin: Comparative antibiotic susceptibility in anaerobes associated with female reproductive tract infection. 8th Mediterranean Congress of Chemotherapy, Athens, Greece, May 24-29, 1992.

112. McGregor JA, Phillips LE, Dunne JT, Warwaruk AS, Johnston DW, Yuzpe AA, Roy S, Hensell DL. Results of a controlled clinical trial comparing ceftizoxime with multiple-dose cefoxitin as prophylaxis for patients undergoing vaginal and abdominal hysterectomy. First European Congress for Infection Diseases in Obstetrics and Gynecology, Taormina, Italy, June 14-19, 1992.

113. Draper D, Beutz M, Jones W, Farbes K, French JI, Heine P, Fogleman J, McGregor JA. Characterization of Trichomonas vaginalis from pregnant women by fatty acid profile using the microbial identification system. Infectious Disease Society for Obstetrics-Gynecology, San Diego, August 6-8, 1992.

114. McGregor JA, Livengood C, French JI, Thomason J, Newton E, Soper D. Intravaginal metronidazole gel (0.75%) for bacterial vaginosis: Results of a double-blinded, randomized, placebo-controlled trial. Infectious Disease Society for Obstetrics-Gynecology, San Diego, August 6-8, 1992.

115. Galask R, Bowdler N, Petzold R, McKinney PJ, McGregor JA. An open-label, pilot study of vaginal pH adjustment following single dose intravaginal administration of a buffered gel at pH 4. Infectious Disease Society for Obstetrics-Gynecology, San Diego, August 6-8, 1992.

116. Galask RP, Bowdler N, Petzold R, McGregor JA. Gram stain correlation with clinical diagnosis of bacterial vaginosis from multi-center trials. Infectious Disease Society for Obstetrics-Gynecology, San Diego, August 6-8, 1992.

117. French JI, McGregor JA, Jones W, Parker R, Patterson E, Brown C, Draper D. Vaginal Phospholipase A2 (PLA2) activity correlates with preterm birth. Infectious Diseases Society for Obstetrics and Gynecology, San Diego, August 6-8, 1992.

118. McGregor JA, French JI, Jones W, Parker R, Patterson E, Draper D. Increased vaginal phospholipase A2 (PLA2) associated with maternal genital microbial abnormalities and preterm birth. Interscience Conference on Antimicrobial Agents and Chemotherapy, Anaheim, California, October 11-14, 1992.

119. Crombleholme W, Newton E, McGregor JA, Tuomala R, Sweet R, Gibbs R. Randomized Comparison of Ampicillin/Sulbactam (A/S) versus Cefoxitin/Doxycycline (C/D) or Clindamycin/Gentamicin (C/G) in the treatment of Pelvic Infections. Interscience Conference on Antimicrobial Agents and Chemotherapy, Anaheim, California, October 11-14, 1992.

120. Heine P, Patterson E, Parker R, Draper D, French JI, Jones W, McGregor JA. Culture is more effective than "saline wet prep" in diagnosing Trichomonas vaginalis in a largely asymptomatic inner-city pregnant population at risk for preterm birth. Society of Perinatal Obstetricians, San Francisco, California, February 8-13, 1993.

121. Blanco J, Iams J, Artal R, Baker D, Hibbard J, McGregor JA, Cetrulo C. Multi-center double-blind prospective random trial of ceftizoxime vs. placebo in women with preterm premature ruptured membranes (pPROM). Society of Perinatal Obstetricians, San Francisco, California, February 8-13, 1993.

122. McGregor JA, Kostraba J, Overman B, French JI, Parker R, Jones W. Microbiologic and "microecologic" evaluation of women at risk for preterm delivery: Results of cluster and discriminant analysis. Society of Perinatal Obstetricians, San Francisco, California, February 8-13, 1993.

123. McGregor JA, French JI, Jones W, Parker R. Vaginal mucinase and sialidase: Correlations with bacterial vaginosis and preterm birth (PTB) and PROM. Society of Perinatal Obstetricians, San Francisco, California, February 8-13, 1993.

124. Blanco J, Iams J, Artal R, Baker D, Hibbard J, McGregor JA, Cetrulo C, pPROM Ceftizoxime Study Group. Multi-center double-blind prospective random trial of ceftizoxime vs. placebo in women with preterm premature ruptured membranes. Society of Perinatal Obstetricians, San Francisco, California, February 8-13, 1993.

125. Heine P, Patterson E, Parker R, Draper D, French JI, Jones W, McGregor JA. Culture is more effective than "saline wet prep" in diagnosing trichomonas vaginalis in a largely asymptomatic inner-city pregnant population at risk for preterm birth. Society of Perinatal Obstetricians, San Francisco, California, February 8-13, 1993.

126. McGregor JA, Hastings C, Browning D, Sibley L, University of Colorado Health Sciences Center, Denver, CO. Intravaginal 2% clindamycin cream for bacterial vaginosis: Results of a double-blinded randomized controlled trial of 7 days vs. 3 days of treatment. ESIDOG Meeting, Cambridge, UK, June 20, 1993.

127. McGregor JA, French JI, Parker R, Draper D, Jones W, Heine P, Patterson E, Hastings C, Thorsgard K. Vaginal fluid enzymes in pregnancy: correlation with cervico/vaginal infections. Infectious Diseases Society for Obstetrics and Gynecology, Stowe, Vermont, August 4-7, 1993

128. McGregor JA, Kostraba J, Overman B, French JI, Parker R, Jones W. Microbiologic and "microecologic" evaluation of women at risk for preterm delivery: results of cluster and discriminate analysis. Infectious Diseases Society for Obstetrics and Gynecology, Stowe, Vermont, August 4-7, 1993.

129. Draper D, McGregor JA, Jones W, Humble D, Brown D, Chandler P, Hanson J, Correia G, Gendru R. Improved diagnosis of symptomatic trichomonas vaginalis (TV) infections in women by the affirm VP III microbial identification test. Infectious Diseases Society for Obstetrics and Gynecology, Stowe, Vermont, August 4-7, 1993.

130. Heine P, Draper D, Jones W, French JI, McGregor JA. Vaginal fluid enzymes correlate with wet mount positivity but not symptomatology in pregnant patients infected with trichomonas vaginalis (TV). Infectious Diseases Society for Obstetrics and Gynecology, Stowe, Vermont, August 4-7, 1993.

131. Draper D, McGregor JA, Hall J, Jones W, Beutz M, Heine P, Porreco R. Increased protease activity and degradation of protease inhibitors in human amniochorion correlates with preterm premature rupture of membranes. Infectious Diseases Society for Obstetrics and Gynecology, Stowe, Vermont, August 4-7, 1993.

132. Gibbs R, McGregor JA, Mead P, Eschenbach D, Hager W, Sweet R. Future efforts in continuing medical education (CME): lessons from the 1992 survey of practice in infectious diseases. Infectious Diseases Society for Obstetrics and Gynecology, Stowe, Vermont, August 4-7, 1993.

133. Draper D, McGregor JA, Jones W, Humble D, Brown D, Chandler P, Hanson J, Correia G, Gendrum RM. Improved diagnosis of symptomatic trichomonas vaginalis (TV) infections in women by the Affirm VP III Microbial Identification Test. Infectious Diseases Society for Obstetrics and Gynecology, Stowe, Vermont, August 4-8, 1993.

134. Jeremias J, Draper D, Ziegert M, Jones W, Ingles S, McGregor JA, Witkin S, Cornell University Medical College, New York, NY and University of Colorado Health Sciences Center, Denver, CO. Detection of trichomonas vaginalis by the polymerase chain reaction (PCR). Infectious Diseases Society for Obstetrics and Gynecology, Stowe, Vermont, August 4-7, 1993.

135. Draper D, McGregor JA, Hall J, Jones W, Beutz M, Heine P, Porreco R. Increased Protease Activity and Degradation of Protease Inhibitors in Human Amniochorion Correlates with preterm premature rupture of membranes. Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, Louisiana, October 17-23, 1993.

136. McGregor JA, French JI, Jones W, Draper D, Parker R, Patterson E, Hastings C, Thorsgard K, McKinney PJ. Correlation of genital tract infection with vaginal fluid virulence factor enzymes in pregnancy: results of a prospective study of 1,260 women. Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, Louisiana, October 17-23, 1993.

137. Draper D, Jones W, Heine P, McGregor JA. Protease activity of Trichomonas vaginalis JI, Jones W, Draper D, Parker R, Patterson E, Hastings C, Thorsgard K, McKinney PJ. Correlation of genital tract infection with vaginal fluid virulence factor enzymes in pregnancy: results of a prospective study of 1260 women. Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, Louisiana, October 17-23, 1993.

138. McGregor JA, French JI, Parker R, Draper D, Jones W, Patterson E, Thorsgard K, Hastings C, McKinney P, Elron I, McFee J. Oral treatment of bacterial vaginosis (BV) reduces preterm birth and rupture of membranes: Results of a prospective controlled treatment trial. Annual Meeting of the Infectious Diseases Society for Obstetrics and Gynecology, Monterey, California, August 3-6, 1994.

139. McGregor JA. A Multi-center Randomized Controlled Trial of Home Uterine Monitoring (HUAM): Active versus SHAM Device. 15th Annual Meeting, Society for Obstetricians, Atlanta, Georgia, January 23-28, 1995.

140. French JI, McGregor JA, Draper D, Parker R, McFee J. Early Gestational Bleeding and Bacterial Vaginosis Increase Risks of Preterm Birth. 15th Annual Meeting, Society for Perinatal Obstetricians, Atlanta, Georgia, January 23-28, 1995.

141. Krems J, McGregor JA, Hastings C, Hanson J. Fetal Fibronectin in Cervical Secretions: An Aid or Predicting Delivery in Women at High Risk for Preterm Delivery. 15th Annual Meeting, Society for Perinatal Obstetricians, Atlanta, Georgia, January 23-28, 1995.

142. Jackson GM, McGregor JA, Lachelin GCL, Goodwin TM, Artal R, Dullien V. Salivary Estriol Rise Predicts Preterm Labor. 15th Annual Meeting, Atlanta, Georgia, January 23-28, 1995.

143. Lachelin GCL, McGarregle HHG, McGregor JA, Jackson GM, Goodwin TM, Artal R, Dullien V. Premature rise in salivary estriol in women going into preterm labor. Br Congress Obstet Gynecol, Dublin, Ireland. 1996.

144. Goodwin TM, Jackson GM, McGregor JA, Lachelin GCL, Artal R, Dullien V. Increased incidence of preterm labor and preterm delivery associated with increased salivary estriol level. 16th Annual Meeting, Society of Perinatal Obstetricians. Kona, Hawaii. February 4-10, 1996.

145. McGregor JA, Parson A. Pathogens on the move: Active uterine transport of cervico-vaginal fluid into and through the uterus and fallopian tubes. Presented at the 4th International Symposium on Bacterial Vaginosis, London, UK, October 31-November 3, 1996.

146. French JI, McGregor JA, Draper D, Parker R, McFee J. Early gestational bleeding and bacterial vaginosis increase risks of preterm birth. Presented at the 4th International Symposium on Bacterial Vaginosis, London, UK, October 31-November 3, 1996.

147. McGregor JA, French JI. Evidence-based on prevention of preterm birth/PROM infection and inflammation. Presented at the 4th International Symposium on Bacterial Vaginosis, London, UK, October 31-November 3, 1996.

148. French JI, McGregor JA, Jones W, Draper D, Parker R, McFee J. Bacterial Vaginosis and increased vaginal fluid phospholipase A2: Defining women at risk for preterm birth. Presented at the 4th International Symposium on Bacterial Vaginosis, London, UK, October 31-November 3, 1996.

149. McGregor JA, Barrett J, Hastings CA. Diurnal variation of salivary estriol in pregnancy. Presented at the 17th Annual Meeting of the Society of Perinatal Obstetricians, Anaheim, CA, January 20-25, 1997.

150. Romero R, Silver H, Koltun W, Millar L, Wang L, Smith J, Creasy G, and the Antocin PTL 098 Study Groups. A double-blind placebo-controlled trial of oxytocin receptor antagonist (Antocin) maintenance therapy in patients with preterm labor. Presented at the 17th Annual Meeting of the Society of Perinatal Obstetricians, Anaheim, CA, January 20-25, 1997.

151. Silver H, Valenzuela, Sanchez-Ramos L, Romero R, Sibai B, Goodwin T, Veille JC, Smith J, Shangolf G, Creasy G, and the Antocin PTL 098 Study Groups. Maternal side effects and safety of the oxytocin receptor antagonist AntocinÔ. Presented at the 17th Annual Meeting of the Society of Perinatal Obstetricians, Anaheim, CA, January 20-25, 1997.

152. Sibai BM, Romero R, Sanchez-Ramos L, Valenzuela G, Veille JC, Tabor B, Morrison J, Varner M, Goodwin T, Menard K, Lane R, Smith J, Creasy G for the Antocin PTL 096 Group. Presented at the 17th Annual Meeting of the Society of Perinatal Obstetricians, Anaheim, CA, January 20-25, 1997.

153. McGregor JA. Lethal obstetrical infections: an important cause of maternal mortality worldwide. Presented at the 1st World Congress on Maternal Mortality, Marrakesh, Morocco, March 8-14, 1997.

154. McGregor JA, Parsons A. Pathogens on the move: active uterine transport of cervico-vaginal fluid into and through the uterus and fallopian tubes. Presented at the 1st World Congress on Maternal Mortality, Marrakesh, Morocco, March 8-14, 1997.

155. French JI, McGregor JA, Draper D, Parker R, McFee J. Early gestational bleeding and bacterial vaginosis increase risks of preterm birth. Presented at the 1st World Congress on Maternal Mortality, Marrakesh, Morocco, March 8-14, 1997.

156. Baker DA, McGregor JA, Monif GRG. Once-daily modified-release oral metronidazole is more effective than clindamycin vaginal cream in the treatment of bacterial vaginosis. Presented at the International Infectious Diseases Society of America, Las Vegas, NV, April 25-26,1997.

157. McGregor JA, Hager WD, Gibbs RS, Schmidt L, Schulkin J. Assessment of Infection Disease Care Practices and Antibiotic Choices by Office-Based Obstetricians and Gynecologists. Infec Dis in Obstet & Gynecol, 6(2): 92, 1998.

Published References

1. Burnhill MJ, McGregor JA, McNeely SG, Pastoreck JG, Wolner-Hensen P. Insights on STD epidemics: a roundtable discussion. Parke-Davis, Morris Plains, NJ 1988.

2. University of Texas Health Sciences Center Symposium on "Management of Vulvovaginal Candidiasis", November 3-4, 1990. Clinical highlights published in Medical Monitor, April 1991, Volume 1, Number 1.

3. Wilson K, McGregor J, Schroer K. HPV in bladders of women with interstitial cystitis. Webster Clinical Investigative Societies, February, 1992.

National/International Presentations

1. McGregor JA. New Approaches to the prevention of preterm birth: Treatment of Chlamydia. Ob/Gyn Care in the 1990s. The Chlamydia Challenge. ACOG Clinical Meeting, San Francisco, CA, May 6, 1990.

2. Intramuscular imipenem/cilistatin for the treatment of upper genital tract infection in women. 7th Mediterranean Congress of Chemotherapy, Barcelona, Spain, May 20-25, 1990.

3. Chair, Controversies and Progress in OB/GYN Infectious Disease. ACOG Postgraduate Course, April 28-April 30, 1992, Las Vegas, NV.

4. Chair, Antibiotic Choices in Obstetrics and Gynecology. ACOG Postgraduate Course, 1992.

5. Serum Parameters of Infection with Preterm Birth. Klinikum Groshadern Ludwig-Maximilians Universitat, Munich, Germany, February, 1993.

6. Chair, Controversies in Ob-Gyn Infectious Diseases, ACOG Postgraduate Course, May 1994, 1995, 1996.

7. McGregor, JA. Gynecologic Infections. The National Program to Prevent Unintended Pregnancy. Clinical Challenges in Contraception: A Program on Women With Special Medical Conditions. ARHP Clinical Proceedings. January 1994, p. 12.

8. McGregor, JA. The New Paradigm in STD/PID/HIV. ACOG Clinical Meeting. San Francisco, CA, 1995.

9. McGregor JA, French JI. Evidence based prevention of preterm birth/PROM: Infection and inflammation. Acta Obstet Gynecol Scand 75: S095, 1996.

10. McGregor JA. Perinatal Infections: HIV, HPV, Herpes Viruses. Seventh Annual Conference on Prevention of Prematurity and Neonatal Mortality. Atlanta, GA. March 14-16, 1996.

11. McGregor JA, Parson A. Pathogens on the move: Active uterine transport of cervico-vaginal fluid into and through the uterus and fallopian tubes. Presented at the 4th International Symposium on Bacterial Vaginosis, London, UK, October 31-November 3, 1996.

12. French JI, McGregor JA, Draper D, Parker R, McFee J. Early gestational bleeding and bacterial vaginosis increase risks of preterm birth. Presented at the 4th International Symposium on Bacterial Vaginosis, London, UK, October 31-November 3, 1996.

13. McGregor JA, French JI. Evidence-based on prevention of preterm birth/PROM infection and inflammation. Presented at the 4th International Symposium on Bacterial Vaginosis, London, UK, October 31-November 3, 1996.

14. French JI, McGregor JA, Jones W, Draper D, Parker R, McFee J. Bacterial Vaginosis and increased vaginal fluid phospholipase A2: Defining women at risk for preterm birth. Presented at the 4th International Symposium on Bacterial Vaginosis, London, UK, October 31-November 3, 1996.

15. McGregor JA. Lethal obstetrical infections: an important cause of maternal mortality worldwide. Presented at the 1st World Congress on Maternal Mortality, Marrakesh, Morocco, March 8-14, 1997.

16. McGregor JA, Parsons A. Pathogens on the move: active uterine transport of cervico-vaginal fluid into and through the uterus and fallopian tubes. Presented at the 1st World Congress on Maternal Mortality, Marrakesh, Morocco, March 8-14, 1997.

17. French JI, McGregor JA, Draper D, Parker R, McFee J. Early gestational bleeding and bacterial vaginosis increase risks of preterm birth. Presented at the 1st World Congress on Maternal Mortality, Marrakesh, Morocco, March 8-14, 1997.

Grants, Funded Studies

1. Double-blinded, randomized controlled trial evaluation of Ceforanide vs. Cefoxitin in women with pelvic infections. 1979-1981, Sponsor - Bristol Meyers Co., $20,000.

2. Evaluation of Cefadroxil in the treatment of abdominal wound infections following Obstetrical/Gynecologic surgery. 1982-83, Sponsor: Bristol Labs. $20,000.

3. Non-comparative study of parenteral Cefotaxime sodium in the treatment of hospitalized patients with pelvic inflammatory disease caused by susceptible bacteria. 1982-1984, Sponsor: Hoechst Roussel, Co.

4. Evaluation of virulence factor production by reproductive tract microorganisms, 1982-1985, Sponsor: The Upjohn Company, $5,000.

5. Randomized, Prospective Study of Parental Ceftriaxone vs. Cefoxitin in the treatment of hospitalized patients with pelvic inflammatory disease caused by susceptible bacteria. 1983, Spon-sor: Hoffman-LaRoche. $50,000.

6. Chancellor's Faculty Research Award, University of Colorado Health Science Center, Denver, Colorado, 1984, $10,000.

7. NIH Grant: Microorganisms and host interactions in preterm birth. #1 RO1 HD20288-01. Bacteriology. Approved, but not funded, 1985.

8. An open label, non-comparative study of the safety, tolerance and efficacy of intravenous Timentin in the treatment of adult hospitalized patients with intra-abdominal and/or gynecologic infections. 1985-1986, Sponsor: Beecham Laboratories, $60,000.

9. A multi-clinic, open study of the efficacy, safety, and tolerance of intramus-cular Primaxin (MK0787/MK0791 or Imipenem/Cilastatin) in the treatment of hospitalized female patients with mild to moderate post-partum endomyometritis. 1985-1986, Sponsor: Merck Sharp and Dohme, $9,600.

10. Multi-center, open, comparative study of intravenous cefotetan 1 Gram and Mefoxin as prophylac-tic agents in cesarean section. 1985-1986, Sponsor: Stuart Pharmaceuticals. $100,000.

11. Efficacy and systemic absorption of 2% Clindamycin phosphate vaginal cream in pregnant women with bacterial vaginosis. 1986, Sponsor: The Upjohn Co. $24,000.

12. NIH Grant: Prevention of preterm birth and ruptured membranes. #1 RO1 HD22102-01. Approved, but not funded, 1986.

13. Evaluation of Adjunctive Therapy of Preterm Labor & Correlation with Lower Genital Tract Microbiologic Studies. 1986 - 1990. Sponsor: Upjohn, $50,000.

14. A multi-clinic, open study of the efficacy, safety, and tolerance of intramuscular Primaxin (MK0787/MK0791 or Imipenem/Cilistatin) in the treatment of hospitalized female patients with mild to moderate gynecologic infections. 1986-1987, Sponsor: Merck Sharp and Dohme, $24,000.

15. Multi-center, open, comparative study of intravenous cefotetan 1 Gram and Mefoxin (Cefoxitin sodium) as prophylactic agents in women undergoing vaginal or abdominal hysterectomy. 1986-1987, Sponsor: Stuart Phar-maceuticals. $40,000.

16. Comparison of intravenous cefmetazole and cefoxitin in the treatment of gynecologic pelvic infection. 1986-1987, Sponsor: The Upjohn Company, $30,000.

17. NIH Grant: Impact of Diet on Pregnancy Outcome in Mexican Americans. Department of Ob/Gyn, UCHSC, Department Nutrition, Colorado State University. Applied for 1987.

18. United States Congress, Office of Technology Assessment. Preven-tion of Infertility 1987. $7,000. Published 1988.

19. A double-blind, prospective randomized comparative study of single dose Cefoxitin vs. Cefotetan in prophylactic treatment of patients following cesarean sections. 1987-present. Sponsor: Merck Sharp & Dohme, $100,000.

20. Randomized, prospective, comparative, parallel study of parenteral Ampicillin plus sulbactam versus Cefoxitin/Doxycycline (Clindamycin/Gen-tamicin) in the treatment of postpartum obstetrical infections of bacterial etiol-ogy. 1987- 1989, Sponsor: Roerig Pfizer Pharmaceuticals, $250,000.

21. Prospective, double-blind, comparative study of intravenous CefizoxÔ (ceftizoxime sodium) 1 gm vs. intravenous MefoxinÔ (cefoxitin sodium) 2 gms x 3 as prophylactic agents in women undergoing hysterectomy 1988-1991, Sponsor: Smith, Kline, and French Laboratories. $125,000.

22. Efficacy of Clindamycin Vaginal Cream in the prevention of preterm labor in pregnant women with bacterial vaginosis. 1987-1990, Sponsor: The Upjohn Company, $100,000.

23. Multi-center, double-blinded, comparative study of single intravenous doses of Ampicillin/Sulbactam (2g/1g) vs. Cefoxitin sodium (2g) as chemoprophylaxis vs. infectious morbidity in cesarean section patients. 1989-1992, Sponsor: Roerig/Pfizer Pharmaceuticals, $220,000.

24. Efficacy of Clindamycin Vaginal Cream vs. Triple Sulfonamide Vaginal Cream in the Treatment of Bacterial Vaginosis. A Randomized Double-Blind Trial. 1988-1990, Sponsor: The Upjohn Company, $30,000.

25. Evaluation of Intravaginal Metronidazole Gel vs Intravaginal Placebo Gel for the Treatment of Bacterial Vaginosis. 1989-1990, Sponsor: Curatek Pharmaceuticals, $15,000.

26. Evaluation of Piperacillin/Tazobactam versus Clindamycin/Gentamicin in treatment of hospitalized patients with gynecologic infections of bacterial etiology. 1989-1992, Sponsor: American Cyanamid Company, $46,000.

27. A multi-center, randomized, comparative study of the safety, efficacy and tolerance of Cefpirome versus Cefoxitin in prophylactic treatment of hospitalized patients undergoing cesarean section. 1989-1990, Sponsor: Hoechst-Roussel Pharmaceuticals, $127,600.

28. Open label and efficacy pilot trial of 0.75% Metronidazole vaginal gel administered to female patients with Trichomonas vaginalis infection.1990,Sponsor: Curatek Pharmaceuticals, $7,500.

29. A multi-center, observer blind, randomized study of the safety, efficacy and tolerance of Cefpirome versus Cefotetan in prophylactic treatment of hospitalized patients undergoing elective abdominal hysterectomy. 1990, Sponsor: Hoechst-Roussel Pharmaceuticals, $27,000.

30. Evaluation of Meropenem and Clindamycin plus Gentamicin in the treatment of hospitalized patients with obstetric and gynecologic infections.1990-1992, Sponsor: ICI Pharmaceuticals.

31. Multi-center, double-blind placebo, controlled study of the effect of ceftizoxime sodium in the management of patients with preterm premature rupture of membranes. 1990-1992. Sponsor: Fijisawa Pharmaceuticals.

32. Evaluation of 3 versus 7 days of 2% clindamycin cream as treatment for bacterial vaginosis. 1993-1994, Sponsor: Upjohn Laboratories, $50,000.

33. Study of metronidazole vaginal gel vs oral metronidazole in treatment of bacterial vaginosis. 1993-1994, Sponsor: Upjohn Laboratories, $50,000.

34. Evaluation of the PTD checkTM enzyme immunoassay as an aid for the deletion of pregnant women at elevated risk for preterm delivery. 1992-1993. Sponsor: Adeza Biomedical, $9,504.

35. Use of the fetal fibronectin enzyme immunoassay as an aid for the detection of delivery in women with high risk for preterm delivery. 1992-1993. Sponsor: Adeza Biomedical, $35,200.

36. Evaluation of 3 days vs 7 days of miconazole for the treatment of vaginal candidiasis. 1993-1994, Sponsor: Miles Pharmaceuticals.

37. Study of enzymatic mean to identify vaginal pathogens using DNA technologies. 1992-1994. Sponsor: Microprobe, Seattle.

38. Early detection of enzymatic methods to diagnose vaginal infections. 1990-1994. Sponsor: Litmus, $30,000.

39. Enzymatic characterization of fetal fibronectin in vaginal fluid. Quality Control. 1993-1994, Sponsor: Adeza Biomedical.

40. Study of stability and transport characterizations of vaginal diagnostic specimens. 1992, Sponsor: Microprobe, $20,000.

41. Pilot study of the efficacy of clindamycin vaginal cream to eradicate Group B steptococcus (GBS) in pregnancy. 1993-1995. Sponsor: The Upjohn Company, $1360.80/patient.

42. Evaluation of the epidemiology of indeterminent HIV-1 antibody status. Prevention of HIV-1 vertical transmission by passive maternal immunization. Co-investigator. NIH#AI-32915-04. $779,660.

43. An open label, pilot study of vaginal pH adjustment following single-dose intravaginal administration of a buffered gel at pH 4. Protocol #E/B-pH-02-01-0391-2. 1991. Sponsor: Curatek Pharmaceuticals, $20,080.

44. A multi-center, randomized study to compare the safety and efficacy of oral levofloxacin with that of ceftriaxone/doxycycline in the treatment of pelvic inflammatory disease. Protocol M92-026. 1992-1994. Sponsor: RW Johnson Pharmaceutical Research Institute.

45. A prospective, randomized evaluation of ampicillin/sulbactam versus clindamycin/gentamicin for the treatment of chorioamnionitis. 1991-1995. Sponsor: Pfizer Pharmaceuticals.

46. A prospective, randomized, double-blind, placebo controlled evaluation of ampicillin/sulbactam versus clindamycin as adjunctive treatment for women experiencing preterm labor. 1992-1995. Sponsor: Pfizer Pharmaceuticals.

47. The safety and efficacy of 0.75% metronidazole vaginal gel versus oral metronidazole for the treatment of T. vaginalis vaginitis. Protocol #E/MTVPO-02-02-892. 1993. Sponsor: Curatek Pharmaceuticals.

48. Single dose prophylaxis for infection after cesarean section in high risk patients: 1.0 gram cefmetazole compared with 1.0 gram cefotelan. Protocol M/1160/0034. 1991-1992. Sponsor: The Upjohn Company.

49. Prophylaxis for postoperative infection in vaginal hysterectomy: single-dose cefmetazole sodium compared to cefotetan disodium. Protocol M/1160/0029. 1990-1992. Sponsor: The Upjohn Company.

50. A randomized, comparative trial of aztreonan plus clindamycin versus gentamicin plus clindamycin in the treatment of post-partum endometritis. Protocol 18554-183. 1991-1992. Sponsor: Bristol-Myers Squibb US Pharmaceuticals, $24,000.

51. A multi-center, prospective, randomized, double-blind, parallel group comparison of the clotrimazole 3-day treatment regimen with the clotrimazole 7-day treatment regimen for the treatment of vulvovaginal candidiasis. 1993-1994. Sponsor: Mile Inc.

52. Prospective evaluation of associations between elevated maternal serum alpha fetoprotein, reproductive tract infection and placental villitis and preterm birth. 1995-present. Department of Obstetrics and Gynecology, University of Colorado Health Sciences Center. $9,950. 12/14/94-12/31/98.

53. Treatment of gynecologic/pelvic infections with intravenous trospectomycin sulfate (U-63-366F) with aztreonam or clindamycin phosphate with aztreonam. Protocol M1350/0004. 1990-1991. Sponsor: The Upjohn Company, $70,500.

54. Treatment of gynecologic/pelvic infections with intravenous trospectomycin sulfate (U-63-366F) with aztreonam or clindamycin phosphate with aztreonam. Protocol M1350/0005. 1991-1992. Sponsor: The Upjohn Company.

55. A single blind, clinical efficacy/safety study: Trospectomycin sulfate IV versus cefoxitin sodium IV plus doxycycline IV, both followed by oral doxycycline, in the treatment of pelvic inflammatory disease. Protocol M1350-0003. 1992. Sponsor: Biopharm, $8200.

56. A comparative study of the safety and efficacy of temafloxacin (Abbott-63004) HCL versus cefoxitin sodium plus doxycycline in the treatment of acute gynecologic infections/pelvic inflammatory disease, including acute salpingitis, endometritis, tubo-ovarian abscess, and pelvic peritonitis. Protocol M90-415. 1991-1992.

57. Evaluation of intravaginal metronidazole gel versus intravaginal sultrin cream for the treatment of bacterial vaginosis. Protocol MS/13V-03-12158. 1990-1991. Sponsor: Curatek Pharmaceutical, $22,500.

58. Salivary estriol in the prediction of premature labor. A pilot study (Phase I). 1992-1993. Sponsor: Biex, Inc.

59. Salivary estriol in the prediction of premature labor. A multi-centered pilot study (Phase II). 1993. Sponsor: Biex, Inc., $112,700.

60. A randomized, double-blind, multi-center trial assessing the safety and efficacy of intravenous CP-116, 517 followed by oral CP-99,219 compared with intravenous cefoxitin followed by oral amoxicillin/clavulanic acid for the treatment of acute pelvic infections. Protocol 154-144. 1995. Sponsor: Pfizer, Inc.

61. An evaluation of feminine hygiene practices and their relation to pelvic inflammatory disease (PID). Protocol #MD-00999. 1995-present. Sponsor: SmithKline Beecham, $1,075/patient.

62. A randomized, comparative evaluation of the efficacy of duraprep versus iodophor preparation for surgical skin preparation of women undergoing cesarean section. 1993. Sponsor: 3M Company.

63. A double-blind placebo-controlled safety and efficacy study of AntocinTM maintenance therapy in preterm labor. Protocol Antocin-PTL-098. Co-investigator. 08/04/1994-12/31/1998. Sponsor: RW Johnson Pharmaceutical Research Institute, $170,718.

64. Monitoring of salivary estriol as a risk assessment marker for idiopathic preterm labor in high risk women. 1995-1997. Sponsor: Biex, Inc., $150,000.

65. A randomized double-blind study comparing two dosing regimen of fluconazole for the treatment of acute vaginal candidiasis in women with severe and/or recurrent infections. 1993-1995. Sponsor: Pfizer, Inc.

66. Efficacy of clindamycin vaginal ovule (3 day treatment) versus clindamycin vaginal cream (7 day treatment) in bacterial vaginosis. Protocol M/1114/0001. 1994-1997. Sponsor: The Upjohn Company, $39,690.

67. A randomized, multi-center, investigator-blind, comparative trial of CP-116,517/CP-99,219 and cefoxitin/doxycyline for the treatment of acute pelvic inflammatory disease (PID) in hospitalized subjects. Protocol 154-122. 1995-1996. Sponsor: Pfizer, Inc.

68. A randomized, multi-center, double-blind, double-dummy, comparative trial of CP-99,219 and ofloxacin/clindamycin for the treatment of acute pelvic inflammatory disease (PID) in ambulatory subjects. Protocol 154-125. 1995-1996. Sponsor: Pfizer, Inc.

69. Salivary estriol as a predictor of PTL (Phase II). 1993-1994. Sponsor: Biex, Inc., $139,040.

70. Diurnal variations in salivary estriol during pregnancy. 1994-1995. Sponsor: Biex, Inc., $17,601.

71. Effects of food and drink on salivary estriol. 1995. Sponsor: Biex, Inc., $10,500.

72. Effects of chewing paraffin on salivary estriol. Sponsor: Biex, Inc., $1,055.

73. Stability of frozen versus fresh samples of salivary estriol. 1994-1995. Sponsor: Biex, Inc., $2,549.

74. Effects of toothbrushing on salivary estriol, effects of toothbrushing and bleeding gums on salivary estriol, effects of toothbrushing and mouthwashing on salivary estriol. 1995. Sponsor: Biex, Inc., $7,250.

75. Collection of saliva for lab testing of salivary estriol. 1995. Sponsor: Biex, Inc., $2,500.

76. Sampling processing evaluation of salivary estriol. 1995. Sponsor: Biex, Inc., $2,961.

77. Indicard-BV-Vaginitis detection test. 1994. Sponsor: Litmus Concepts, $17,000.

78. Biological influence on the behavior of infants and toddlers. Gabel S, Olds D, Co-principal investigators, McGregor JA study site coordinator. 1995-1997. Sponsor: The Children's Hospital, $10,000.

79. Treatment of bacterial vaginosis with metronidazole modified release tablet - a dose duration study. 1995 - 1997, GD Searle and Co.

80. A randomized, multi-center, double-blind, double-dummy comparative trial of CP-99, 219 and ofloxacin/clindamycin for the treatment of acute pelvic inflammatory disease (PID) in ambulatory subjects (PID-154-125). Sponsor: Pfizer Inc. Principal Investigator 1995-1996.

81. A randomized, multi-center, investigator-blind, comparative trial of CP-116, 517/ CP-99, 219 and cefoxitin/doxycycline for the treatment of acute pelvic inflammatory disease (PID) in hospitalized subjects (PID-154-122). Sponsor: Pfizer Inc. Principal Investigator 1995-1996.

82. A randomized, double-blind, multi-center, trial assessing the safety and efficacy of intravenous CP-116, 517 followed by oral CP-99, 219 compared with intravenous cefoxitin followed by oral amoxicillin/clavulanic acid for the treatment of acute pelvic infections (PID-154-144). Sponsor: Pfizer Inc. Principal Investigator 1995-1996.

83. A randomized, double-blind, multi-center, trial of the efficacy and safety of a single oral dose of trovafloxacin compared with intravenous cefoxitin for the prophylaxis of infection following elective abdominal or vaginal hysterectomy (154-146). Sponsor: Pfizer Inc. Principal Investigator 1995-1996.

84. Evaluation of feminine hygiene practices and their relation to pelvic inflammatory disease (PID). Sponsor: International Pharmaceutical Research. Principal investigator 08/09/1995-12/31/1998.

85. A double-blind, randomized, comparative, multi-center study of clinafloxacin (CCCCI-960) versus cefotetan in the treatment of acute pelvic infections (protocol 960-036). Sponsor: Parke-Davis. Principal investigator 1996-1997.

86. Associations between unexplained elevated maternal serum alpha fetoprotein reproductive tract infection and preterm birth. A neonatal case control study. Department Obstetrics and Gynecology, University of Colorado Health Sciences Center $4054. Principal investigator 1995-Present.

87. Development of rapid diagnostic tests for the detection of vaginal infections. Sponsor: Diagnostic Markers, Inc. Principal investigator 1996-1997.

88. Telomerase activity in cervical pap smear samples. Department Obstetrics and Gynecology, University of Colorado Health Sciences Center $8154. Co-investigator 1996-Present.

89. An open-label, multicenter safety and efficacy study of 5% topical Imiquimod cream in the treatment of visible, external genital/perineal warts in male and female patients. 10/16/96-12/31/98. Sponsor: 3M, $14,700, no salary support.

90. Safety and efficacy comparison of 5% boric acid vaginal gel and 2% miconazole nitrate cream in the treatment of symptomatic yeast vulvovaginitis: A single-blind, randomized, multicenter, parallel comparison (Protocol BOR-004). 04/02/98-10/31/98. Sponsor: Curatek Pharmaceutical Inc. Initial amount: $45,000 (additional support 06/30/98). Percent time: 5%.

91. A multienter, randomized trial of oral versus intravaginal metronidazole for the treatment of bacterial vaginosis; Pathogen migration and upper genital tract inflammation study (N13-98-02-033). Sponsor: Searle. Amount: $100,000 (no salary support); percent time: 5%. 08/01/98-12/31/98 (pending).

92. Randomized, single-blind comparison of compliance and side effect frequency between Flagyl-ERÒ and oral metronidazole: A pilot study of the incidence of altered taste (N13-07-02-030). Sponsor: Searle, amount: $30,050.80 (no salary support); percent time: 1%. 01/01/98-08/03/98.

Unfunded Research
Preterm Labor -

1. Protease production by microorganisms associated with reproductive tract infection. 1982-1985, Department Obstetrics and Gynecology, Department Microbiology/Immunology, University of Colorado Health Sciences Center.

2. Differential antimicrobial effects of protease production in reproductive tract microorganisms. 1983-1985, Department Obstetrics and Gynecology, Department of Microbiology/Immunology, University of Colorado Health Sciences Center.

3. Adjunctive Antimicrobial Therapy of Preterm Labor. 1982-1985. Department Obstetrics and Gynecology, University of Colorado Health Sciences Center.

4. Prospective, randomized, double-blinded study of adjunctive antimicrobial treatment in patients with preterm premature ruptured membranes. 1984-1988, Department Obstetrics and Gynecology, University of Colorado Health Sciences Center, The Upjohn Company.

5. Evaluation of Bacterial Virulence Factors in the Vaginal/Cervical Microecology of Pregnant Women. 1985-1986, Department Ob/Gyn UCHSC, Children's Hospital.

6. In vitro evaluation of bacterial virulence factor and inflammatory cell enzyme impairment of chorioamniotic membrane strength and elasticity. 1984-present, Department Ob/Gyn UCHSC, and The Kempe Research Center, The Children's Hospital.

7. Double-Blinded, Prospective Study of a Defined Course of Erythromycin in Reducing Short Gestations Correlated with Lower Genital Tract Microbiologic Studies. 1986-1988, Department Ob/Gyn, UCHSC, Children's Hospi-tal.

8. Vaginal Fluid Sampling for Bacterial Virulence Factors: Evaluation of Three Techniques of Sample Collection. 1987-1988, Department Ob/Gyn, UCHSC, Children's Hospital.

9. Influence of dietary fatty acids on gestation among laboratory rats. 1987-1988, Department Ob/Gyn, UCHSC; Department Nutrition, CSU,

10. Influence of Dietary Lipids in Preterm Labor: A Case Control Study. 1987-1988, Department Ob/Gyn UCHSC, Rose Hospital; Department of Nutrition, CSU; Department Biometrics & Preventive Medicine, UCHSC.

11. Fetal gender differences in pregnancies complicated by preterm birth, low birthweight, premature rupture of membranes, and maternal infection. 1988, Department Ob/Gyn, Department Microbiology/Immunology, UCHSC.

12. The Denver Demonstration Project: Evaluation of treatment of bacterial vaginosis, trichomonas, chlamydia, and GBS bacterial during pregnancy (1260 women). 1993, Department Ob/Gyn, UCHSC.

13. Essential fatty acid status during pregnancy in relation to pregnancy outcome. An international study. 1990-1993. Co-investigator.

14. Evaluation of prostaglandin progenitors in preterm labor. 1990-1994, Co-investigator.

15. Identification and treatment of bacterial vaginosis in the prevention of preterm birth. Co-investigator. 1995 - present, Kaiser Permanente Medical Group of Colorado.

16. Investigation of telephone triage for vaginitis. 1995, Allen-Davis J, Parker R, McGregor JA.

17. Prevention of early-onset neonatal sepsis and meningitis among minority and underserved populations. Co-investigator. 1995 - 1996, Centers for Disease Control and Prevention.

18. Evaluation of fetal fibronectin assay utilization in a clinical setting. 1995-1996, Tokos Medical Corp.

Gynecologic Infections:

1. Evaluation of Sexual Practices and Psychological Parameters of Women with Community Acquired Acute Salpingitis. Department Obstetrics and Gynecology, University of Colorado Health Sciences Center.

2. Objectivation and Quantitation of Patient Values and Teaching Regarding Pelvic Inflammatory Disease: Team Proposal. University of Colorado Health Sciences Center.

3. Health focus of control among women with pelvic inflammatory disease. 1983-1985, Department Obstetrics and Gynecology, School of Nursing, University of Colorado Health Sciences Center.

4. Effects of prenatal care on maternal and newborn outcomes 1988, Department Obstetrics and Gynecology; Department of Pediatrics; Department of Biometrics and Preventive Medicine, University of Colorado Health Sciences Center.

Other:

1. Localization of fibronectin in the lower genital tract, 1984-1985.

2. Evaluation of electronic fetal monitoring in the septic perinate 1985-1986, Department Obstetrics and Gynecology, University of Colorado Health Sciences Center.

3. Varicella-zoster antibody testing in the care of pregnant women exposed to varicella, 1986.

4. The collection and storage of umbilical cord blood for transplantation, 1997.

Video Productions

1. McGregor JA, Evans TN. Sexually transmissible diseases: Lower reproductive tract. First Image Video Journal of Medicine 1(4): January-February, 1986.

2. McGregor JA. Sexually transmissible diseases: Upper reproductive tract. First Image Video Journal of Medicine 1(5): March-April, 1986.

3. McGregor JA, Cohn DL. AIDS: Women and babies. First Image Video Journal of Medicine 1(5): March-April, 1986.

4. McGregor JA. Upper genital infection. First Image Video Journal of Medicine, 1986.

5. McGregor JA, Eschenbach D. Upper Genital Tract Infections in Women. Merck Sharp & Dohme, 1987.

6. McGregor JA. Eating Disorders. Berlex Inc. and Biomedical Communications, Seacaucus, New Jersey.

7. McGregor JA. Obstetrics and Gynecology Update: PROM. Lifetime Medical Television, Astoria, New York.

8. McGregor JA. Antibiotic Choices in Obstetrics and Gynecology. An educational service of The American College of Obstetricians and Gynecologists.

9. McGregor JA. Premature Rupture of Membranes. Audio-Digest Obstetrics & Gynecology, Highlights from ACOG Annual Meeting, Washington, DC, May, 1993.

10. McGregor JA. Fatal Infections in Pregnancy. Audio-Digest Obstetrics & Gynecology, Highlights from ACOG Annual Meeting, Washington, DC, July 1993.

11. McGregor JA, Allen-Davis J. Prevention of HIV in Women, Berlex Pharmaceuticals, New York, NY, 1993.

12. McGregor JA. Diagnosis and treatment of bacterial vaginosis. Audio-Digest Obstetrics & Gynecology, OB/GYN Infections Part II, Vol. 41, #03, February 1, 1994.

13. McGregor JA, Allen-Davis J. Primary Care Issues in OB/Gyn Medicine: Women and HIV Infection, Positive Health Decisions Video, #9.

14. McGregor JA. Current Concepts in the Diagnosis and Management of Vulvovaginal Candidiasis, SynerMed, September 16, 1994.

15. McGregor JA. Systemic Versus Topical Antifungal Treatment. Jefferson Med College, 1994.

16. McGregor JA. Concepts and Consensus on Vulvovaginal Candidiasis. Gardiner-Synermed. 1995.

17. McGregor JA. Focus on Female Health: New Strategies in Preventing Preterm Birth/PROM: Infection and Inflammation. Searle, 1996.

Consultations

1. McGregor JA. Pelvic Inflammatory Disease: A Threat to Your Reproductive Health. Krames
Communications, 1989.

2. McGregor JA. Understanding Laparoscopy: Small Incision Surgery for the Female Reproductive Organs.

Acknowledgements

1. Stewart FH, Guest FJ, Stewart G, Hatcher RA. Contraceptive Tech-nology. 1986-1987. Multiple chapters. New York, Ir-vington, 1985.

2. Stewart FH, Guest FJ, Stewart G, Harcher RA. Woman's Body, Woman's Health. Bantam, New York, 1984.

3. Zakis G, Wilday S. Adolescent Abortion, Social Work in Health Care, Vol 12(4), Summer 1987.

4. McGregor JA. Pelvic Inflammatory Disease: A threat to your reproductive health. Krames Communication, San Francisco, CA, 1989.

5. Borgatta L, Nickinovich D. Pain during early abortion. J Repro Med (in press, 1997.)

meet our advisors, women's health, obstetrics, gynecology, infertility, pregnancy, hysterectomy, fibroids, and more

OBGYN.net: The Universe of Women's Health

OBGYN.net Editorial Advisor
Obstetrics, Pregnancy & Birth
Correspondent

meet our advisors, women's health, obstetrics, gynecology, infertility, pregnancy, hysterectomy, fibroids, and more

OBGYN.net: The Universe of Women's Health

OBGYN.net Editorial Advisor Obstetrics, Pregnancy & Birth Correspondent

OBGYN.net Editorial Advisor
Obstetrics, Pregnancy & Birth
Correspondent